Publications

1. Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, Karnes RJ, Kwon ED, Childs DS, Andrews JR. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27 (2):334-338 Epub 2023 Nov 07
   View PubMed
2. Tekin B, Sali AP, Menon S, Cheville JC, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Cubilla AL, Whaley RD, Hernandez LH, Jimenez RE, Garcia JJ, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S. Comparison of a modified staging system with 8th edition AJCC criteria in a North American cohort of pT2/pT3 HPV-negative penile squamous cell carcinoma. Hum Pathol. 2024 Jun; 148:81-86 Epub 2024 May 22
   View PubMed
3. Weiner AB, Kakani P, Armstrong AJ, Bossi A, Cornford P, Feng F, Kanabur P, Karnes RJ, Mckay RR, Morgan TM, Schaeffer EM, Shore N, Tree AC, Spratt DE. Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2024 May 22 [Epub ahead of print]
   View PubMed
4. Basourakos SP, Henning G, Karnes RJ. Current evidence on local therapy in oligometastatic prostate cancer. Curr Opin Urol. 2024 May 1; 34 (3):198-203 Epub 2024 Feb 01
   View PubMed
5. Marra G, Rajwa P, Filippini C, Ploussard G, Montefusco G, Puche-Sanz I, Olivier J, Zattoni F, Moro FD, Magli A, Dariane C, Affentranger A, Grogg JB, Hermanns T, Chiu PK, Malkiewicz B, Kowalczyk K, Van den Bergh RCN, Shariat SF, Bianchi A, Antonelli A, Gallina S, Berchiche W, Sanchez-Salas R, Cathelineau X, Afferi L, Fankhauser CD, Mattei A, Karnes RJ, Scuderi S, Montorsi F, Briganti A, Deandreis D, Gontero P, Gandaglia G, EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party (PCa-WP). The Prognostic Role of Preoperative PSMA PET/CT in cN0M0 pN+ Prostate Cancer: A Multicenter Study. Clin Genitourin Cancer. 2024 Apr; 22 (2):244-251 Epub 2023 Nov 17
   View PubMed
6. Campbell RA, Khanna A, Boorjian SA, Knorr J, Cox R, Nicholas M, Cheville J, Sharma V, Murthy PB, Tarrell R, Thapa P, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Haber GP, Lee B. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy. Clin Genitourin Cancer. 2024 Apr; 22 (2):157-163.e1 Epub 2023 Oct 26
   View PubMed
7. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 Apr; 22 (3):140-150
   View PubMed
8. Giesen A, Van den Broeck T, Develtere D, Raskin Y, Wymer K, Eden C, Claessens M, Hente R, Rans K, Berghen C, De Meerleer G, Langley S, Karnes RJ, Heidenreich A, Pfister D, Joniau S. Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post-operative outcomes. World J Urol. 2024 Feb 15; 42 (1):81
   View PubMed
9. Tekin B, Cheville JC, Herrera Hernandez L, Negron V, Smith CY, Jenkins SM, Dasari S, Enninga EAL, Norgan AP, Menon S, Cubilla AL, Whaley RD, Jimenez RE, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Pagliaro LC, Erickson LA, Guo R, Gupta S. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. Hum Pathol. 2023 Dec; 142:42-50. Epub 2023 Nov 15.
   View PubMed
10. Gilani SI, Dasari S, Tekin B, Hernandez LH, Cheville JC, Jimenez RE, Rech KL, Dao LN, Howard MT, Dalland JC, Chiu A, Theis JD, Vrana JA, Grogan M, Thompson RH, Leibovich BC, Karnes RJ, Boorjian SA, Dispenzieri A, McPhail ED, Gupta S. Identification of amyloidosis of the urinary tract and prostate: Opportunities for early diagnosis & intervention in systemic disease. Hum Pathol. 2023 Dec; 142:62-67. Epub 2023 Nov 17.
    View PubMed
11. Preisser F, Incesu RB, Rajwa P, Chlosta M, Nohe F, Ahmed M, Abreu AL, Cacciamani G, Ribeiro L, Kretschmer A, Westhofen T, Smith JA, Steuber T, Calleris G, Raskin Y, Gontero P, Joniau S, Sanchez-Salas R, Shariat SF, Gill I, Karnes RJ, Cathcart P, Van Der Poel H, Marra G, Tilki D. Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. Prostate Cancer Prostatic Dis. 2023 Oct 6 Epub 2023 Oct 06
    View PubMed
12. Rodrigues Pessoa R, Nabavizadeh R, Shah P, Frank I, Tollefson M, Sharma V, Rangel LJ, Cheville JC, Karnes RJ, Boorjian SA. Relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy. Prostate Cancer Prostatic Dis. 2023 Sep 15 Epub 2023 Sept 15
    View PubMed
13. Marra G, Calleris G, Conte F, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Smith JA, Joniau S, Rodriguez-Sanchez L, Sanchez-Salas R, Cathcart P, Gill I, Karnes RJ, Tilki D, Shariat SF, Touijer K, Gontero P. Recurrent Gleason Score 6 Prostate Cancer After Radiotherapy or Ablation: Should We Observe Them All? Results from a Large Multicenter Salvage Radical Prostatectomy Consortium. Eur Urol Focus. 2023 Sep 11 Epub 2023 Sept 11
    View PubMed
14. Britton CJ, Sharma V, Fadel AE, Bearrick E, Findlay BL, Frank I, Tollefson MK, Karnes RJ, Viers BR. Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes. J Urol. 2023 Aug; 210 (2):312-322 Epub 2023 Apr 20
    View PubMed
15. Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer. 2023 Jul 15; 129 (14):2169-2178 Epub 2023 Apr 14
    View PubMed
16. Calleris G, Marra G, Benfant N, Rajwa P, Ahmed M, Abreu A, Cacciamani G, Ghoreifi A, Ribeiro L, Westhofen T, Tourinho-Barbosa R, Raskin Y, Veerman H, Albisinni S, Smith JA, Roupret M, Oderda M, Massari E, Persad R, Van Der Poel H, Joniau S, Sanchez-Salas R, Kretschmer A, Cathcart P, Gill I, Karnes RJ, Tilki D, Shariat SF, Touijer K, Gontero P. Salvage Radical Prostatectomy for Recurrent Prostate Cancer Following First-line Nonsurgical Treatment: Validation of the European Association of Urology Criteria in a Large, Multicenter, Contemporary Cohort. Eur Urol Focus. 2023 Jul; 9 (4):645-649 Epub 2023 Jan 20
    View PubMed
17. Preisser F, Incesu RB, Rajwa P, Chlosta M, Ahmed M, Abreu AL, Cacciamani G, Ribeiro L, Kretschmer A, Westhofen T, Smith JA, Graefen M, Calleris G, Raskin Y, Gontero P, Joniau S, Sanchez-Salas R, Shariat SF, Gill I, Karnes RJ, Cathcart P, Van Der Poel H, Marra G, Tilki D. Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy. Cancers (Basel). 2023 Jun 9; 15 (12) Epub 2023 June 09
    View PubMed
18. Tekin B, Dasari S, Theis JD, Vrana JA, Murray DL, Oglesbee D, Thompson RH, Leibovich BC, Boorjian SA, Whaley RD, Hernandez LH, Jimenez RE, Cheville JC, Karnes RJ, Sukov WR, Gupta S. Mass spectrometry-based assessment of prostate cancer-associated crystalloids reveals enrichment for growth and differentiation factor 15. Hum Pathol. 2023 May; 135:35-44 Epub 2023 Mar 09
    View PubMed
19. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023 Mar 1; 115 (3):645-653 Epub 2022 Sept 28
    View PubMed
20. Myers A, Frank I, Shah PH, Tarrell RF, Baird B, Dora C, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA, Lyon TD. Intraoperative Blood Transfusion Is Associated With Increased Risk of Venous Thromboembolism After Radical Cystectomy. J Urol. 2023 Mar; 209 (3):525-531 Epub 2022 Nov 29
    View PubMed
21. Nabavizadeh R, Karnes RJ. Salvage radical prostatectomy. Curr Opin Urol. 2023 Mar 1; 33 (2):163-167 Epub 2022 Dec 29
    View PubMed
22. Avulova S, Benidir T, Cheville JC, Packiam VT, Shah P, Frank I, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Kulkarni G, Boorjian SA. Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy. Arch Pathol Lab Med. 2023 Feb 1; 147 (2):202-207
    View PubMed
23. Kemble J, Kwon ED, Karnes RJ. Addressing the need for more therapeutic options in neuroendocrine prostate cancer. Expert Rev Anticancer Ther. 2023 Feb; 23 (2):177-185 Epub 2023 Feb 03
    View PubMed
24. Nabavizadeh R, Karnes RJ. Salvage radical prostatectomy. Current Opinion in Urology. 2023; 33 (2):163-7
    
25. Tekin B, Dasari S, Theis JD, Vrana JA, Murray DL, Oglesbee D, Thompson RH, Leibovich BC, Boorjian SA, Whaley RD, Herrera Hernandez L, Jimenez RE, Cheville JC, Karnes RJ, Sukov WR, Gupta S. Mass spectrometry–based assessment of prostate cancer–associated crystalloids reveals enrichment for growth and differentiation factor 15. Human Pathology. 2023; 135:35-44
    
26. Bravi CA, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann KP, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmuller B, Shariat S, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A, Pfister D. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer. BJUI Compass. 2023 Jan; 4 (1):123-129 Epub 2022 Aug 04
    View PubMed
27. Joyce DD, Soligo M, Morlacco A, Latuche LJR, Schulte PJ, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ. Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy. Eur Urol Open Sci. 2023 Jan; 47:87-93 Epub 2022 Dec 15
    View PubMed
28. Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Tellini R, Campi R, Schulz GB, Black PC, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Mondini F, Simeone C, Antonelli A, Tafuri A, Krajewski W, Malkiewicz B, Xylinas E, Soria F, Sanchez Salas R, Arora A, Cathelineau X, Hendricksen K, Ammiwala M, Borghesi M, Chierigo F, Teoh JY, Mattei A, Albisinni S, Roghmann F, Roumiguie M, Bajeot AS, Maier E, Aziz A, Hurle R, Contieri R, Pradere B, Carando R, Poyet C, Alvarez-Maestro M, D'Andrea D, Shariat SF, Moschini M, European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. Eur Urol Oncol. 2022 Dec; 5 (6):722-725 Epub 2022 June 15
    View PubMed
29. Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 Dec; 208(6):1240-1249. Epub 2022 Nov 09.
    View PubMed
30. Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, Karnes RJ, Kwon E, Lowe VJ, Kendi AT, Bold MS, Pagliaro LC. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022 Dec; 82(16):1483-1490. Epub 2022 Sep 11.
    View PubMed
31. Barletta F, Mazzone E, Stabile A, Scuderi S, Brembilla G, de Angelis M, Cirulli GO, Cucchiara V, Gandaglia G, Karnes RJ, Roupret M, De Cobelli F, Montorsi F, Briganti A. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database. World J Urol. 2022 Nov; 40 (11):2683-2688 Epub 2022 Sept 23
    View PubMed
32. Karnes RJ. Editorial Comment. J Urol 2022 Oct; 208 (4):844-845 Epub 2022 July 15
    View PubMed
33. Marra G, Oderda M, Calleris G, Marquis A, Peretti F, Zitella A, Moschini M, Sanchez-Salas R, Karnes RJ, Kneitz B, Spahn M, Pacchioni D, Gontero P. Ki-67, topoisomerase IIalpha and miR-221 have a limited prostate cancer risk stratification ability on a medium-term follow-up: results of a high-risk radical prostatectomy cohort. Transl Androl Urol. 2022 Sep; 11 (9):1271-1281
    View PubMed
34. Arora A, Zugail AS, Pugliesi F, Cathelineau X, Macek P, Barbe Y, Karnes RJ, Ahmed M, Di Trapani E, Soria F, Alvarez-Maestro M, Montorsi F, Briganti A, Necchi A, Pradere B, D'Andrea D, Krajewski W, Roumiguie M, Bajeot AS, Hurle R, Contieri R, Carando R, Teoh JY, Roupret M, Benamran D, Ploussard G, Mir MC, Sanchez-Salas R, Moschini M. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. World J Urol. 2022 Jul; 40 (7):1697-1705 Epub 2022 Apr 30
    View PubMed
35. Afferi L, Lonati C, Montorsi F, Briganti A, Necchi A, Mari A, Minervini A, Campi R, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Simeone C, Krajewski W, Xylinas E, Soria F, Hendricksen K, Einerhand S, Mattei A, Carando R, Roumiguie M, Bajeot AS, Black PC, Shariat SF, Moschini M, European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. World J Urol. 2022 Jun; 40 (6):1489-1496 Epub 2022 Feb 10
    View PubMed
36. Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, Shariat SF, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Roupret M, Montironi R, Moschini M, European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? Urol Oncol. 2022 Jun; 40 (6):273.e11-273.e20 Epub 2022 Feb 23
    View PubMed
37. Kensler KH, Awasthi S, Alshalalfa M, Trock BJ, Freedland SJ, Freeman MR, You S, Mahal BA, Den RB, Dicker AP, Karnes RJ, Klein EA, Lal P, Liu Y, Davicioni E, Rayford W, Yamoah K, Rebbeck TR. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. Eur Urol Open Sci. 2022 Jun; 40:19-26 Epub 2022 Apr 26
    View PubMed
38. Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmuller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. Eur Urol Oncol. 2022 Jun; 5 (3):285-295 Epub 2021 June 24
    View PubMed
39. Lonati C, Mordasini L, Afferi L, De Cobelli O, Di Trapani E, Necchi A, Colombo R, Briganti A, Montorsi F, Simeone C, Zamboni S, Simone G, Karnes RJ, Marra G, Soria F, Gontero P, Shariat SF, Pradere B, Hendricksen K, Ammiwala M, Rink M, Poyet C, Krajewski W, Baumeister P, Mattei A, Moschini M, Carando R, European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology - Young Academic Urologists. Urol Oncol. 2022 May; 40 (5):195.e27-195.e35 Epub 2022 Feb 27
    View PubMed
40. Ahmed ME, Todenhofer T, Karnes RJ, Seiler R. Prognostic Role of RNA Expression Molecular Biomarkers in Prostate and Bladder Cancers. Eur Urol Focus. 2022 May; 8 (3):663-666 Epub 2022 July 14
    View PubMed
41. Tanaka T, Kawashima A, Rangel LJ, Schulte PJ, Froemming AT, King BF, Mynderse LA, Karnes RJ. Long-Term Risk of Clinical Progression Utilizing Magnetic Resonance Imaging Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence following Radical Prostatectomy. J Urol. 2022 May; 207 (5):1038-1047 Epub 2022 Jan 04
    View PubMed
42. Van den Broeck T, Moris L, Gevaert T, Davicioni E, Boeckx B, Lambrechts D, Helsen C, Handle F, Ghesquiere B, Soenen S, Smeets E, Eerlings R, El Kharraz S, Devlies W, Karnes RJ, Lotan T, Van Poppel H, Joniau S, Claessens F. Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. Mol Cancer Res. 2022 Apr 1; 20 (4):527-541
    View PubMed
43. Weiner AB, Liu Y, McFarlane M, Bawa PS, Li EV, Zhao X, Li Z, Hammoud T, Hazime M, Karnes RJ, Davicioni E, Reichert ZR, Chinnaiyan AM, Lotan TL, Spratt DE, Schaeffer EM. A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer Prostatic Dis. 2022 Apr; 25 (4):659-665 Epub 2021 July 05
    View PubMed
44. Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr; 81 (4):325-330 Epub 2020 Dec 07
    View PubMed
45. Shkedi A, Taylor IR, Echtenkamp F, Ramkumar P, Alshalalfa M, Rivera-Marquez GM, Moses MA, Shao H, Karnes RJ, Neckers L, Feng F, Kampmann M, Gestwicki JE. Selective vulnerabilities in the proteostasis network of castration-resistant prostate cancer. Cell Chem Biol. 2022 Mar 17; 29 (3):490-501.e4 Epub 2022 Feb 01
    View PubMed
46. Khanna A, Miest T, Sharma V, Campbell R, Hensley P, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Murthy PB, Haber GP, Navai N, Kamat AM, Dinney C, Lee B, Boorjian SA. Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. J Urol. 2022 Mar; 207(3):551-558. Epub 2021 Oct 25.
    View PubMed
47. Karnes RJ. Editorial Comment. J Urol 2022 Mar; 207 (3):591 Epub 2021 Dec 15
    View PubMed
48. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer a patient-level data analysis of 3 cohorts. JAMA Oncology. 2022 Mar; 8 (3):e216871
    
49. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 1; 8 (3):e216871 Epub 2022 Mar 17
    View PubMed
50. Lonati C, Baumeister P, Ornaghi PI, Di Trapani E, De Cobelli O, Rink M, Karnes RJ, Poyet C, Simone G, Afferi L, Necchi A, Briganti A, Montorsi F, Krajewski W, Antonelli A, Cerruto MA, Zamboni S, Simeone C, Mordasini L, Mattei A, Moschini M, EAU-YAU Urothelial Cancer Working Party. Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. Eur Urol Focus. 2022 Mar; 8 (2):457-464 Epub 2021 Apr 16
    View PubMed
51. Miest T, Khanna A, Sharma V, Hensley PJ, Campbell R, Thapa P, Zganjar A, Tollefson MK, Thompson RH, Frank I, Karnes RJ, Potretzke A, Matin SF, Murthy PB, Haber GP, Lee B, Boorjian SA. Development and Validation of a Risk-Adapted Scoring Model for Metachronous Upper Tract Urothelial Carcinoma following Radical Cystectomy. J Urol. 2022 Feb; 207(2):284-292. Epub 2021 Sep 22.
    View PubMed
52. Sorce G, Stabile A, Luciano R, Motterle G, Scuderi S, Barletta F, Pellegrino F, Cucchiara V, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Jeffrey Karnes R, Karnes RJ, Guccini I, Briganti A. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. BJU Int. 2022 Feb; 129 (2):201-207 Epub 2021 June 13
    View PubMed
53. Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ Jr, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13; 3 (1) Epub 2021 Nov 19
    View PubMed
54. Jimbo M, Andrews JR, Ahmed ME, Dundar A, Karnes RJ, Bryce AH, Kendi AT, Kwon ED, Lowe VJ, Bold MS. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate. 2022 Jan; 82(1):41-48. Epub 2021 Oct 11.
    View PubMed
55. Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 Dec 21; 12 (1):7349
    View PubMed
56. Weiner AB, Faisal FA, Davicioni E, Karnes RJ, Griend DJV, Lotan TL, Schaeffer EM. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. Eur Urol Oncol. 2021 Dec; 4 (6):955-962 Epub 2020 June 12
    View PubMed
57. Stabile A, Barletta F, Motterle G, Pellegrino F, Sorce G, Mazzone E, Scuderi S, Cirulli GO, Cucchiara V, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Briganti A. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. Prostate Cancer Prostatic Dis. 2021 Dec; 24 (4):1137-1142 Epub 2021 May 03
    View PubMed
58. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 Dec 1; 4 (12):e2138550 Epub 2021 Dec 01
    View PubMed
59. Ma TM, Xiang M, Tilki D, Karnes RJ, Stish BJ, Martinez-Monge R, Tendulkar RD, Klein EA, Tran PT, Tosoian J, Berlin A, Tward JD, Merrick GS, Spratt DE, Krauss DJ, Horwitz EM, Gafita A, Grogan T, Calais J, Kishan AU. Prognostic Significance of the Risk of Non-localized Disease on PSMA/PET: Comparative Performance of a Novel, PSMA/PET-Derived Risk Stratification Tool for High-Risk Prostate Cancer in a Large, Multi-Institutional Cohort. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S51-S52
    View PubMed
60. Mazzone E, Stabile A, Sorce G, Pellegrino F, Barletta F, Motterle G, Scuderi S, Cirulli GO, Cucchiara V, Brembilla G, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Guccini I, Briganti A. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? Urol Oncol. 2021 Nov; 39 (11):784.e1-784.e9 Epub 2021 Apr 15
    View PubMed
61. Martini A, Afferi L, Zamboni S, Schultz JG, Lonati C, Mattei A, Karnes RJ, Soligo M, Stabile A, Di Trapani E, De Cobelli O, Simone G, Simeone C, Alvarez-Maestro M, Gandaglia G, Gallina A, Colombo R, Briganti A, Montorsi F, Xylinas E, Shariat SF, Moschini M. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. J Urol. 2021 Oct; 206 (4):885-893 Epub 2021 May 25
    View PubMed
62. Khanna A, Zganjar A, Lyon T, Shah P, Tollefson MK, Karnes RJ, Tarrell R, Thapa P, Thompson RH, Frank I, Boorjian SA. A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy. J Urol. 2021 Oct; 206 (4):970-977 Epub 2021 May 25
    View PubMed
63. Andrews JR, Hebert KJ, Boswell TC, Avant RA, Boonipatt T, Kreutz-Rodrigues L, Bakri K, Houdek MT, Karnes RJ, Viers BR. Pubectomy and urinary reconstruction provides definitive treatment of urosymphyseal fistula following prostate cancer treatment. BJU Int. 2021 Oct; 128 (4):460-467 Epub 2021 Feb 17
    View PubMed
64. Zhang J, Gao K, Xie H, Wang D, Zhang P, Wei T, Yan Y, Pan Y, Ye W, Chen H, Shi Q, Li Y, Zhao SM, Hou X, Weroha SJ, Wang Y, Zhang J, Karnes RJ, He HH, Wang L, Wang C, Huang H. SPOP mutation induces DNA methylation via stabilizing GLP/G9a. Nat Commun. 2021 Sep 29; 12 (1):5716 Epub 2021 Sept 29
    View PubMed
65. Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, Den RB, Trock BJ, Karnes RJ, Klein EA, Freeman MR, You S. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021 Sep; 24 (3):733-742 Epub 2021 Feb 02
    View PubMed
66. Sharma V, Karnes RJ. Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study. Eur Urol 2021 Sep; 80 (3):385 Epub 2021 June 24
    View PubMed
67. Huang Z, Tang B, Yang Y, Yang Z, Shi L, Bai Y, Yan B, Karnes RJ, Zhang J, Jimenez R, Wang L, Wei Q, Yang J, Xu W, Jia Z, Huang H. MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression. Cancer Res. 2021 Sep 1; 81 (17):4471-4484 Epub 2021 June 22
    View PubMed
68. Miest TS, Sharma V, Karnes RJ, Boorjian SA, Thompson RH, Frank I, Tollefson MK. Incidence and predictors of occult preoperative deep vein thrombosis at radical cystectomy for urothelial carcinoma. Can Urol Assoc J. 2021 Sep; 15 (9):E471-E475
    View PubMed
69. Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2021 Sep; 80 (3):280-292 Epub 2020 Dec 11
    View PubMed
70. Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, Briganti A. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. Eur Urol Oncol. 2021 Aug; 4 (4):594-600 Epub 2019 June 14
    View PubMed
71. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021 Aug; 80 (2):142-146 Epub 2021 May 10
    View PubMed
72. Alshalalfa M, Abou-Ouf H, Davicioni E, Karnes RJ, Alhajj R, Bismar TA. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. J Cancer Res Clin Oncol. 2021 Aug; 147 (8):2223-2231 Epub 2021 Apr 16
    View PubMed
73. Li P, Taylor JMG, Spratt DE, Karnes RJ, Schipper MJ. Evaluation of predictive model performance of an existing model in the presence of missing data. Stat Med. 2021 Jul 10; 40 (15):3477-3498 Epub 2021 Apr 11
    View PubMed
74. Marra G, Calleris G, Alessio P, Oderda M, Palou J, Joniau S, Piechaud T, Smelzo S, Morlacco A, Sharma V, Tilki D, Van der Poel H, Veerman H, Karnes RJ, Gontero P. Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies? Eur Urol Focus. 2021 Jul; 7 (4):807-811 Epub 2020 May 12
    View PubMed
75. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open. 2021 Jul 1; 4 (7):e2115312 Epub 2021 July 01
    View PubMed
76. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larre S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. Actas Urol Esp (Engl Ed). 2021 Jul-Aug; 45 (6):473-478 Epub 2021 June 17
    View PubMed
77. Pisano F, Gontero P, Sylvester R, Joniau S, Serretta V, Larre S, Di Stasi S, van Rhijn B, Witjes A, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients. Actas Urol Esp. 2021 Jul-Aug; 45 (6):473-478 Epub 2021 May 13
    View PubMed
78. Packiam VT, Labbate CV, Boorjian SA, Tarrell R, Cheville JC, Avulova S, Sharma V, Tsivian M, Adamic B, Mahmoud M, Werntz RP, Smith ND, Karnes RJ, Tollefson MK, Steinberg GD, Frank I. The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. Urol Oncol. 2021 Jul; 39 (7):436.e1-436.e8 Epub 2021 Jan 21
    View PubMed
79. Miest TS, Sharma V, Boeri L, Tollefson MK, Thompson RH, Boorjian SA, Frank I, Karnes RJ. Does Ureteral Stent Drainage Prior to Cystectomy Increase the Risk of Subsequent Upper Tract Urothelial Carcinoma and Ureteral Complications? Urology. 2021 Jul; 153:215-220 Epub 2020 Aug 05
    View PubMed
80. Ahmed ME, Andrews JR, Joshi VB, Mynderse LA, Tollefson MK, Karnes RJ, Kwon ED. Patient Satisfaction of Telemedicine Visits in an Advanced Prostate Cancer Clinic During the COVID-19 Pandemic. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun; 5 (3):689-692 Epub 2021 May 26
    View PubMed
81. Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer. 2021 Jun; 19 (3):246-254.e5 Epub 2020 Aug 13
    View PubMed
82. Chu CE, Alshalalfa M, Sjostrom M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 Jun; 79 (6):717-721 Epub 2021 Apr 08
    View PubMed
83. Boeri L, Sharma V, Kwon E, Stish BJ, Davis BJ, Karnes RJ. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 Jun; 24 (2):514-523 Epub 2020 Dec 02
    View PubMed
84. Ahmed ME, Joshi VB, Badawy M, Pagliaro LC, Karnes RJ, Lowe V, Thorpe MP, Kwon ED, Kendi AT. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS. Clin Genitourin Cancer. 2021 Jun; 19 (3):223-229 Epub 2021 Jan 07
    View PubMed
85. Lyon TD, Frank I, Tollefson MK, Tarrell RF, Shah PH, Thompson RH, Karnes RJ, Boorjian SA. Association of intraoperative hypothermia with oncologic outcomes following radical cystectomy. Urol Oncol. 2021 Jun; 39 (6):370.e1-370.e8 Epub 2020 Dec 08
    View PubMed
86. Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, Karnes RJ, Trock BJ, Klein EA, Den RB, Demichelis F, Davicioni E, Sboner A, Barbieri CE. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021 May 17; 131 (10)
    View PubMed
87. Ahmed ME, Phillips RM, Sharma V, Davis BJ, Karnes RJ. Oligometastatic prostatic cancer recurrence: role of salvage lymph node dissection (sLND) and radiation therapy-stereotactic body radiation therapy (RT-SBRT). Curr Opin Urol. 2021 May 1; 31 (3):199-205
    View PubMed
88. Heidenreich A, Karnes RJ. Editorial: Salvage therapy in uro-oncology. Curr Opin Urol 2021 May 1; 31 (3):177
    View PubMed
89. Marra G, Karnes RJ, Calleris G, Oderda M, Alessio P, Palazzetti A, Battaglia A, Pisano F, Munegato S, Munoz F, Filippini C, Ricardi U, Linares E, Sanchez-Salas R, Goonewardene S, Dasgupta P, Challacombe B, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Smelzo S, Piechaud T, Taille A, Roupret M, Albisinni S, van Velthoven R, Morlacco A, Vidit S, Gandaglia G, Mottrie A, Smith J, Joshi S, Fiscus G, Berger A, Aron M, Abreu A, Gill IS, Van Der Poel H, Tilki D, Murphy D, Lawrentschuk N, Davis J, Gontero P. Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: A multicenter retrospective study. Urol Oncol. 2021 May; 39 (5):296.e21-296.e29 Epub 2021 Jan 10
    View PubMed
90. Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Bohmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol Oncol. 2021 Apr; 4 (2):301-304 Epub 2019 Dec 04
    View PubMed
91. Cacciamani GE, Maas M, Nassiri N, Ortega D, Gill K, Dell'Oglio P, Thalmann GN, Heidenreich A, Eastham JA, Evans CP, Karnes RJ, De Castro Abreu AL, Briganti A, Artibani W, Gill I, Montorsi F. Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. Eur Urol Oncol. 2021 Apr; 4 (2):134-149 Epub 2021 Mar 06
    View PubMed
92. Dinh TT, Mitin T, Bagshaw HP, Hoffman KE, Hwang C, Karnes RJ, Jeffrey Karnes R, Kishan AU, Liauw SL, Lloyd S, Potters L, Showalter TN, Taira AV, Vapiwala N, Zaorsky NG, D'Amico AV, Nguyen PL, Davis BJ. Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 Mar 15; 109 (4):953-963 Epub 2020 Oct 27
    View PubMed
93. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE. A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol. 2021 Mar; 79 (3):374-383 Epub 2020 Dec 05
    View PubMed
94. Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F, Briganti A, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez-Maestro M, Martinez-Pineiro L, Aziz A, Shariat SF, Abufaraj M, Xylinas E, Moschini M, European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. World J Urol. 2021 Feb; 39 (2):443-451 Epub 2020 Apr 30
    View PubMed
95. Takahashi H, Froemming AT, Bruining DH, Karnes RJ, Jimenez RE, Takahashi N. Prostate MRI characteristics in patients with inflammatory bowel disease. Eur J Radiol. 2021 Feb; 135:109503 Epub 2021 Jan 05
    View PubMed
96. Kim SP, Karnes RJ, Mwangi R, Van Houten H, Gross CP, Gershman B, Leapman MS, Shah ND. Contemporary Trends in Magnetic Resonance Imaging at the Time of Prostate Biopsy: Results from a Large Private Insurance Database. Eur Urol Focus. 2021 Jan; 7 (1):86-94 Epub 2019 Apr 29
    View PubMed
97. Ding YC, Wu H, Davicioni E, Karnes RJ, Klein EA, Den RB, Steele L, Neuhausen SL. Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. J Transl Genet Genom. 2021; 5:50-61 Epub 2021 Mar 09
    View PubMed
98. Abou-Ouf H, Assem H, Ghosh S, Karnes RJ, Stoletov K, Palanisamy N, Lewis JD, Bismar TA. High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. Eur Urol Open Sci. 2021 Jan; 23:1-8 Epub 2020 Dec 02
    View PubMed
99. Awasthi S, Berglund A, Abraham-Miranda J, Rounbehler RJ, Kensler K, Serna A, Vidal A, You S, Freeman MR, Davicioni E, Liu Y, Karnes RJ, Klein EA, Den RB, Trock BJ, Campbell JD, Einstein DJ, Gupta R, Balk S, Lal P, Park JY, Cleveland JL, Rebbeck TR, Freedland SJ, Yamoah K. Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. Clin Cancer Res. 2021 Jan 1; 27 (1):320-329 Epub 2020 Oct 09
    View PubMed
100. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 1; 109 (1):174-185 Epub 2020 Aug 27
     View PubMed
101. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 Dec 1; 6 (12):1912-1920
     View PubMed
102. Ahmed ME, Khalil MI, Kamel MH, Karnes RJ, Spiess PE. Progress on Management of Penile Cancer in 2020. Curr Treat Options Oncol. 2020 Nov 23; 22 (1):4
     View PubMed
103. Packiam VT, Tsivian M, Avulova S, Sharma V, Tarrell R, Cheville JC, Frank I, Thompson RH, Tollefson MK, Gettman MT, Karnes RJ, Thapa P, Boorjian SA. Long-term outcomes of incidental prostate cancer at radical cystectomy. Urol Oncol. 2020 Nov; 38 (11):848.e17-848.e22 Epub 2020 July 02
     View PubMed
104. Arriaga JM, Panja S, Alshalalfa M, Zhao J, Zou M, Giacobbe A, Madubata CJ, Kim JY, Rodriguez A, Coleman I, Virk RK, Hibshoosh H, Ertunc O, Ozbek B, Fountain J, Jeffrey Karnes R, Karnes RJ, Luo J, Antonarakis ES, Nelson PS, Feng FY, Rubin MA, De Marzo AM, Rabadan R, Sims PA, Mitrofanova A, Abate-Shen C. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat Cancer. 2020 Nov; 1 (11):1082-1096 Epub 2020 Oct 19
     View PubMed
105. Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, Kim HL, Klein EA, Davis JW, Ross AE, Tosoian JJ, Morgan TM, Mehra R, Salami SS, Nguyen PL, Lawton CAF, Spratt DE, Feng F. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precis Oncol. 2020 Nov; 4:1228-1238
     View PubMed
106. Joseph JP, Glasgow AE, Carlson RE, Frank I, Tollefson MK, Boorjian SA, Thompson RH, Karnes RJ, Habermann EB, Gettman MT. Screening Postoperative Hemoglobin after Robot-Assisted Radical Prostatectomy-Frequently Used, but Is It Necessary? Urol Pract. 2020 Nov; 7(6):554-558. Epub 2019 Dec 02.
     View PubMed
107. Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G, EAU-YAU Prostate Cancer Working Party. Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. Eur Urol Oncol. 2020 Oct; 3 (5):565-581 Epub 2020 Sept 12
     View PubMed
108. Andrews JR, Ahmed ME, Motterle G, Albadri ST, Haloi R, Karnes RJ, Kwon ED, Price KA. A Rare Case of Prostate-Specific Antigen-Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance. Mayo Clin Proc Innov Qual Outcomes. 2020 Oct; 4(5):601-607. Epub 2020 Aug 19.
     View PubMed
109. Hong Z, Zhang W, Ding D, Huang Z, Yan Y, Cao W, Pan Y, Hou X, Weroha SJ, Karnes RJ, Wang D, Wu Q, Wu D, Huang H. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3ß and WEE1. Mol Cell. 2020 Sep 17; 79(6):1008-1023.e4. Epub 2020 Aug 31.
     View PubMed
110. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 Sep; 78 (3):327-332 Epub 2020 May 24
     View PubMed
111. Andrews JR, Sobol I, Frank I, Gettman MT, Thompson RH, Karnes RJ, Boorjian SA, Tollefson MK. Treatment Outcomes in Patients With Symptomatic Lymphoceles Following Radical Prostatectomy Depend Upon Size and Presence of Infection. Urology. 2020 Sep; 143:181-185 Epub 2020 June 17
     View PubMed
112. Sharma V, Wymer KM, Borah BJ, Saigal CS, Litwin MS, Packiam VT, Thompson RH, Tollefson MK, Karnes RJ, Boorjian SA. Cost-Effectiveness of Maintenance bacillus Calmette-Guerin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer. J Urol. 2020 Sep; 204 (3):442-449 Epub 2020 Mar 19
     View PubMed
113. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 Aug 20; 38 (24):2798-2811 Epub 2020 June 09
     View PubMed
114. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of (68)Ga-PSMA and (11)C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. J Urol. 2020 Aug; 204 (2):296-302 Epub 2020 Feb 18
     View PubMed
115. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, Briganti A. Reply by Authors. J Urol 2020 Aug; 204 (2):302 Epub 2020 May 19
     View PubMed
116. Choo R, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ. Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? Minerva Urol Nefrol. 2020 Aug; 72 (4):474-481 Epub 2019 July 25
     View PubMed
117. Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol Focus. 2020 Jul 15; 6 (4):642-649 Epub 2019 Nov 08
     View PubMed
118. Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul; 78 (1):29-42 Epub 2020 May 03
     View PubMed
119. Motterle G, Ahmed ME, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution. J Urol. 2020 Jun; 203 (6):1141-1146 Epub 2020 Mar 17
     View PubMed
120. Motterle G, Morlacco A, Zattoni F, Karnes RJ. Prostate cancer: more effective use of underutilized postoperative radiation therapy. Expert Rev Anticancer Ther. 2020 Apr; 20 (4):241-249 Epub 2020 Mar 17
     View PubMed
121. Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. 2020 Apr 1; 126 (7):1407-1412 Epub 2020 Jan 06
     View PubMed
122. Ahmed ME, Motterle G, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Salvage Radical Prostatectomy After Robot-assisted Laparoscopic Prostatectomy: Case Series. Clin Genitourin Cancer. 2020 Apr; 18 (2):e202-e207 Epub 2019 Oct 16
     View PubMed
123. Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? Prostate. 2020 Apr; 80 (5):399-406 Epub 2020 Jan 13
     View PubMed
124. Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Deho F, De Cobelli F, Montorsi F, Karnes RJ, Briganti A. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. Eur Urol Oncol. 2020 Feb; 3 (1):112-118 Epub 2019 Mar 27
     View PubMed
125. Boeri L, Sharma V, Nehra A, Kwon E, Karnes RJ. The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience. Urol Oncol. 2020 Feb; 38 (2):38.e9-38.e16 Epub 2019 Oct 23
     View PubMed
126. Motterle G, Morlacco A, Zanovello N, Ahmed ME, Zattoni F, Karnes RJ, Dal Moro F. Surgical Strategies for Lymphocele Prevention in Minimally Invasive Radical Prostatectomy and Lymph Node Dissection: A Systematic Review. J Endourol. 2020 Feb; 34 (2):113-120
     View PubMed
127. Sharma V, Karnes RJ, Viers BR. Treatment outcomes of bladder neck contractures from surgical clip erosion: a matched cohort comparison. Transl Androl Urol. 2020 Feb; 9 (1):115-120
     View PubMed
128. Lyon TD, Shah ND, Tollefson MK, Shah PH, Sangaralingham LR, Asante D, Thompson RH, Karnes RJ, Frank I, Boorjian SA. AUTHOR REPLY. Urology 2020 Feb; 136:111
     View PubMed
129. Lyon TD, Shah ND, Tollefson MK, Shah PH, Sangaralingham LR, Asante D, Thompson RH, Karnes RJ, Frank I, Boorjian SA. Trends in Extended-Duration Venous Thromboembolism Prophylaxis Following Radical Cystectomy. Urology. 2020 Feb; 136:105-111 Epub 2019 Nov 09
     View PubMed
130. Chys B, Devos G, Everaerts W, Albersen M, Moris L, Claessens F, De Meerleer G, Haustermans K, Briganti A, Chlosta P, Gontero P, Graefen M, Gratzke C, Karnes RJ, Kneitz B, Marchioro G, Salas RS, Spahn M, Tombal B, Van Der Poel H, Walz J, Van Poppel H, Joniau S. Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. Front Oncol. 2020; 10:246 Epub 2020 Mar 06
     View PubMed
131. Yoshida K, Takahashi N, Karnes RJ, Froemming AT. Prostatic Remnant After Prostatectomy: MR Findings and Prevalence in Clinical Practice. AJR Am J Roentgenol. 2020 Jan; 214 (1):W37-W43 Epub 2019 Oct 31
     View PubMed
132. Zattoni F, Bednarova I, Morlacco A, Motterle G, Beltrami P, Dal Moro F, Karnes RJ. Transitional cell carcinoma recurrence impacting intestinal diversion after radical cystectomy. Oncologic outcomes of a rare site of recurrence. Cent European J Urol. 2020; 73 (4):445-456 Epub 2020 Dec 09
     View PubMed
133. Assel MJ, Ulmert HD, Karnes RJ, Boorjian SA, Hillman DW, Vickers AJ, Klee GG, Lilja H. Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. Prostate. 2020 Jan; 80 (1):51-56 Epub 2019 Oct 11
     View PubMed
134. Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, Xu F, Wang Y, Karnes RJ, Dong B, Xue W. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. Urol Oncol. 2019 Dec; 37 (12):991-998 Epub 2019 Aug 27
     View PubMed
135. Morlacco A, Dal Moro F, Rangel LJ, Carlson RE, Soligo M, Karnes RJ. Impact of metabolic syndrome on functional outcomes and complications of surgical treatment of prostate cancer. J Surg Oncol. 2019 Dec; 120 (8):1505-1507 Epub 2019 Nov 12
     View PubMed
136. Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naive Primary Prostate Cancer. Clin Cancer Res. 2019 Nov 15; 25 (22):6721-6730 Epub 2019 Sept 12
     View PubMed
137. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Tarrel R, Quevedo FJ, Cheville JC, Karnes RJ. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience. World J Urol. 2019 Nov; 37 (11):2409-2418 Epub 2019 Feb 25
     View PubMed
138. Sharma V, Wymer KM, Borah BJ, Barocas DA, Thompson RH, Karnes RJ, Boorjian SA. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. J Urol. 2019 Nov; 202 (5):964-972 Epub 2019 Oct 09
     View PubMed
139. Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. Eur Urol Focus. 2019 Nov; 5 (6):1007-1013 Epub 2018 Mar 10
     View PubMed
140. Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Bohmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, Briganti A. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. Eur Urol. 2019 Oct; 76 (4):443-449 Epub 2019 Feb 22
     View PubMed
141. Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Roupret M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ, Collaborators. Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. J Urol. 2019 Oct; 202 (4):725-731 Epub 2019 Sept 06
     View PubMed
142. Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ. (11)C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities. Adv Radiat Oncol. 2019 Oct-Dec; 4 (4):659-667 Epub 2019 July 04
     View PubMed
143. Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. Prostate. 2019 Oct; 79 (14):1589-1596 Epub 2019 Aug 02
     View PubMed
144. Labbe DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, D'Amico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019 Sep 25; 10 (1):4358 Epub 2019 Sept 25
     View PubMed
145. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clin Cancer Res. 2019 Sep 15; 25 (18):5608-5622 Epub 2019 July 02
     View PubMed
146. Van den Broeck T, Moris L, Gevaert T, Tosco L, Smeets E, Fishbane N, Liu Y, Helsen C, Margrave J, Buerki C, Davicioni E, Van Poppel H, Everaerts W, Weinmann S, Den R, Davis J, Schaeffer E, Karnes RJ, Claessens F, Joniau S. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. Eur Urol Oncol. 2019 Sep; 2 (5):589-596 Epub 2019 Jan 11
     View PubMed
147. Calleris G, Marra G, Dalmasso E, Falcone M, Karnes RJ, Morlacco A, Oderda M, Sanchez-Salas R, Soria F, Gontero P. Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World J Urol. 2019 Aug; 37 (8):1469-1483 Epub 2019 Apr 06
     View PubMed
148. Lyon TD, Frank I, Sharma V, Shah PH, Tollefson MK, Thompson RH, Karnes RJ, Thapa P, Cheville JC, Boorjian SA. A risk-stratified approach to neoadjuvant chemotherapy in muscle-invasive bladder cancer: implications for patients classified with low-risk disease. World J Urol. 2019 Aug; 37 (8):1605-1613 Epub 2018 Nov 03
     View PubMed
149. Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, Briganti A, European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol Oncol. 2019 Jul; 2 (4):456-463 Epub 2018 Dec 24
     View PubMed
150. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes. Eur Urol Oncol. 2019 Jul; 2 (4):390-396 Epub 2018 Sept 28
     View PubMed
151. Karnes RJ, Motterle G. Re: Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger than 60 Years. Eur Urol 2019 Jun; 75 (6):1035-1036 Epub 2019 Mar 01
     View PubMed
152. Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, Quevedo FJ, Cheville JC, Karnes RJ. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. BJU Int. 2019 Jun; 123 (6):1011-1019 Epub 2019 Jan 08
     View PubMed
153. Wymer KM, Sharma V, Davis BJ, Kwon ED, Mynderse LA, Karnes RJ. Evaluating the Potential Role of Salvage Vesiculectomy for Prostate Cancer Recurrence. Clin Genitourin Cancer. 2019 Jun; 17 (3):e536-e540 Epub 2019 Feb 06
     View PubMed
154. Westerman ME, Sharma V, Bailey GC, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ. Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy. Int Braz J Urol. 2019 May-Jun; 45 (3):468-477
     View PubMed
155. Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, Briganti A. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. Eur Urol. 2019 May; 75 (5):817-825 Epub 2018 Nov 05
     View PubMed
156. Colicchia M, Morlacco A, Rangel LJ, Carlson RE, Dal Moro F, Karnes RJ. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance. Eur Urol Focus. 2019 May; 5(3):425-432. Epub 2018 Jan 03.
     View PubMed
157. Lyon TD, Boorjian SA, Shah PH, Tarrell R, Cheville JC, Frank I, Karnes RJ, Thompson RH, Tollefson MK. Comprehensive characterization of perioperative reoperation following radical cystectomy. Urol Oncol. 2019 Apr; 37 (4):292.e11-292.e17 Epub 2019 Jan 22
     View PubMed
158. Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019 Apr-Jun; 4 (2):314-322 Epub 2019 Feb 19
     View PubMed
159. Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Goppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, Balk SP, Den RB, Trock BJ, Karnes RJ, Jenkins RB, Klein EA, Davicioni E, Gruhl FJ, Long HW, Liu XS, Cato ACB, Lack NA, Nelson PS, Plymate SR, Groner AC, Brown M. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. 2019 Mar 18; 35 (3):401-413.e6 Epub 2019 Feb 14
     View PubMed
160. Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 1; 38 (5) Epub 2019 Feb 05
     View PubMed
161. Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Bornigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 Mar; 28 (3):584-590 Epub 2018 Nov 12
     View PubMed
162. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjostrom M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. J Natl Cancer Inst. 2019 Mar 1; 111 (3):301-310
     View PubMed
163. Vasmatzis G, Kosari F, Murphy SJ, Terra S, Kovtun IV, Harris FR, Zarei S, Smadbeck JB, Johnson SH, Gaitatzes AG, Therneau TM, Rangel LJ, Knudson RA, Greipp P, Sukov WR, Knutson DL, Kloft-Nelson SM, Karnes RJ, Cheville JC. Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. Mayo Clin Proc. 2019 Jan; 94(1):27-36.
     View PubMed
164. Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ, Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED, Davis BJ, Nathan MA. Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications. Adv Radiat Oncol. 2019 Jan-Mar; 4 (1):79-89 Epub 2018 Sept 05
     View PubMed
165. Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. Eur Urol. 2019 Jan; 75 (1):176-183 Epub 2018 Oct 06
     View PubMed
166. Ma L, Yan Y, Bai Y, Yang Y, Pan Y, Gang X, Karnes RJ, Zhang J, Lv Q, Wu Q, Huang H. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer. Theranostics. 2019; 9 (17):5020-5034 Epub 2019 July 09
     View PubMed
167. Bai Y, Yang Y, Yan Y, Zhong J, Blee AM, Pan Y, Ma T, Karnes RJ, Jimenez R, Xu W, Huang H. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis. Theranostics. 2019; 9 (12):3459-3475 Epub 2019 May 24
     View PubMed
168. Motterle G, Ahmed ME, Andrews JR, Karnes RJ. The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. Front Oncol. 2019; 9:1395 Epub 2019 Dec 10
     View PubMed
169. Salami SS, Kaplan JB, Nallandhighal S, Takhar M, Tosoian JJ, Lee M, Yoon J, Hovelson DH, Plouffe KR, Kaffenberger SD, Schaeffer EM, Karnes RJ, Lotan TL, Morgan TM, George AK, Montgomery JS, Davenport MS, You S, Tomlins SA, Curci NE, Kim HL, Spratt DE, Udager AM, Palapattu GS. Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer. JCO Precis Oncol. 2019; 3 Epub 2019 June 12
     View PubMed
170. Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larre S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. World J Urol. 2018 Nov; 36 (11):1775-1781 Epub 2018 Aug 31
     View PubMed
171. Lyon TD, Frank I, Shah PH, Tarrell R, Cheville JC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. The Association of Aspirin Use with Survival Following Radical Cystectomy. J Urol. 2018 Nov; 200 (5):1014-1021 Epub 2018 May 30
     View PubMed
172. Ravi P, Karnes RJ, Rangel LJ, Pagliaro LC. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. J Urol. 2018 Nov; 200 (5):1075-1081 Epub 2018 Apr 27
     View PubMed
173. Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 Nov; 27 (11):1376-1383 Epub 2018 Aug 14
     View PubMed
174. Moschini M, Sharma V, Soligo M, Psutka S, Rangel L, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Karnes RJ. Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer. Scand J Urol. 2018 Oct - Dec; 52 (5-6):340-348 Epub 2019 Jan 02
     View PubMed
175. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larre S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol. 2018 Oct; 36 (10):1621-1627 Epub 2018 May 02
     View PubMed
176. Karnes RJ, Sharma V, Choeurng V, Ashab HA, Erho N, Alshalalfa M, Trock B, Ross A, Yousefi K, Tsai H, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, Spratt DE, Abdollah F, Jenkins RB, Klein EA, Nguyen PL, Dicker AP, Den RB, Davicioni E, Feng FY, Lotan TL, Schaeffer EM. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. Clin Cancer Res. 2018 Aug 15; 24 (16):3908-3916 Epub 2018 May 14
     View PubMed
177. Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A, Boorjian SA. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. Eur Urol. 2018 Aug; 74 (2):134-137 Epub 2018 Mar 12
     View PubMed
178. Lyon TD, Tollefson MK, Shah PH, Bews K, Frank I, Karnes RJ, Thompson RH, Habermann EB, Boorjian SA. Temporal trends in venous thromboembolism after radical cystectomy. Urol Oncol. 2018 Aug; 36 (8):361.e15-361.e21 Epub 2018 June 07
     View PubMed
179. Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, Tapia ELN, Guerrero M, Karnes RJ, Dicker AP, Hurwitz MA, Nguyen PL, Feng FFY, Freedland SJ, Davis JW. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. Eur Urol. 2018 Jul; 74 (1):107-114 Epub 2017 Dec 10
     View PubMed
180. Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK. Examining the association between adiposity and biochemical recurrence after radical prostatectomy. Can Urol Assoc J. 2018 Jul; 12 (7):E331-E337 Epub 2018 Mar 19
     View PubMed
181. Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 Jun 1; 7 (6)
     View PubMed
182. Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, Briganti A. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol. 2018 Jun; 73 (6):890-896 Epub 2017 Oct 16
     View PubMed
183. Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK. The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. Clin Genitourin Cancer. 2018 Jun; 16 (3):e629-e636 Epub 2017 Dec 06
     View PubMed
184. Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2018 Jun; 73 (6):834-844 Epub 2017 Oct 14
     View PubMed
185. Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy. Eur Urol. 2018 Jun; 73 (6):879-887 Epub 2017 Nov 28
     View PubMed
186. Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy? J Urol. 2018 Jun; 199 (6):1502-1509 Epub 2018 Jan 04
     View PubMed
187. Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmuller B, Gandaglia G, Briganti A, Karnes RJ. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol. 2018 May; 1 (1):46-53 Epub 2018 May 15
     View PubMed
188. Gearman DJ, Morlacco A, Cheville JC, Rangel LJ, Karnes RJ. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance. J Urol. 2018 May; 199 (5):1188-1195 Epub 2017 Dec 07
     View PubMed
189. Zattoni F, Morlacco A, Nehra A, Frank I, Boorjian SA, Thapa P, Karnes RJ. Vaginal cuff recurrence after radical cystectomy: an under - studied site of bladder cancer relapse. Int Braz J Urol. 2018 May-Jun; 44 (3):491-499
     View PubMed
190. Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. J Cancer Res Clin Oncol. 2018 May; 144 (5):883-891 Epub 2018 Mar 06
     View PubMed
191. Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Eur Urol. 2018 Apr; 73 (4):512-518 Epub 2017 Dec 08
     View PubMed
192. Singhal U, Wang Y, Henderson J, Niknafs YS, Qiao Y, Gursky A, Zaslavsky A, Chung JS, Smith DC, Karnes RJ, Chang SL, Feng FY, Palapattu GS, Taichman RS, Chinnaiyan AM, Tomlins SA, Morgan TM. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res. 2018 Apr; 16 (4):643-654 Epub 2018 Feb 16
     View PubMed
193. Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med. 2018 Apr; 10(4).
     View PubMed
194. Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Eur Urol Focus. 2018 Apr; 4 (3):369-375 Epub 2017 Jan 17
     View PubMed
195. Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. Eur Urol. 2018 Apr; 73 (4):524-532 Epub 2017 Mar 19
     View PubMed
196. Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy. Eur Urol Focus. 2018 Mar; 4 (2):288-293 Epub 2015 Dec 24
     View PubMed
197. Nehra A, Parker WP, Haloi R, Park SS, Mynderse LA, Lowe VJ, Davis BJ, Quevedo JF, Johnson GB, Kwon ED, Karnes RJ. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using (11)C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging. J Urol. 2018 Mar; 199 (3):726-733 Epub 2017 Sept 12
     View PubMed
198. Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, Briganti A. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. Eur Urol. 2018 Mar; 73 (3):436-444 Epub 2017 Aug 02
     View PubMed
199. Moschini M, Morlacco A, Briganti A, Hu B, Colombo R, Montorsi F, Frank I, Daneshmand S, Karnes RJ. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. Eur Urol Focus. 2018 Mar; 4 (2):245-251 Epub 2016 Nov 23
     View PubMed
200. Spratt DE, Zhang J, Santiago-Jimenez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2018 Feb 20; 36 (6):581-590 Epub 2017 Nov 29
     View PubMed
201. Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2018 Feb 15; 24 (4):834-846 Epub 2017 Nov 22
     View PubMed
202. Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ. Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series. Urology. 2018 Feb; 112:29-32 Epub 2017 Oct 25
     View PubMed
203. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. Epub 2017 Dec 13.
     View PubMed
204. Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2018 Feb; 73 (2):168-175 Epub 2017 Apr 08
     View PubMed
205. Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol. 2018; 2018 Epub 2018 July 24
     View PubMed
206. Karnes RJ, MacKintosh FR, Morrell CH, Rawson L, Sprenkle PC, Kattan MW, Colicchia M, Neville TB. Prostate-Specific Antigen Trends Predict the Probability of Prostate Cancer in a Very Large U.S. Veterans Affairs Cohort. Front Oncol. 2018; 8:296 Epub 2018 Aug 06
     View PubMed
207. Moschini M, Fossati N, Sood A, Lee JK, Sammon J, Sun M, Pucheril D, Dalela D, Montorsi F, Karnes RJ, Briganti A, Trinh QD, Menon M, Abdollah F. Contemporary Management of Prostate Cancer Patients Suitable for Active Surveillance: A North American Population-based Study. Eur Urol Focus. 2018 Jan; 4 (1):68-74 Epub 2016 June 14
     View PubMed
208. Sharma V, Dong H, Kwon E, Karnes RJ. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells. Eur Urol Focus. 2018 Jan; 4 (1):75-79 Epub 2016 Sept 21
     View PubMed
209. Morlacco A, Murphy CR, Rangel LJ, Mynderse LA, Thompson RH, Karnes RJ. Effect of Level of Urology Training on Gleason Score and Prostate Volume Estimation Agreement between Transrectal Ultrasound Guided Biopsy and Radical Prostatectomy Specimen. Urol Pract. 2018 Jan; 5 (1):76-82 Epub 2016 Dec 07
     View PubMed
210. Westerman ME, Bhindi B, Choo R, Gettman MT, Karnes RJ, Klotz L, Boorjian SA. Media reporting of ProtecT: a disconnect in information dissemination? Prostate Cancer Prostatic Dis. 2017 Dec; 20 (4):401-406 Epub 2017 May 02
     View PubMed
211. Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 Dec; 20 (4):407-412 Epub 2017 May 09
     View PubMed
212. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 Dec 1; 3 (12):1663-1672
     View PubMed
213. Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M, Dell'Oglio P, Suardi N, Montorsi F, Karnes RJ, Briganti A. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Eur Urol. 2017 Dec; 72 (6):910-917 Epub 2017 June 13
     View PubMed
214. Weight CJ, Narayan VM, Smith D, Kim SP, Karnes RJ. The Effects of Population-based Prostate-specific Antigen Screening Beginning at Age 40. Urology. 2017 Dec; 110:127-133 Epub 2017 Aug 24
     View PubMed
215. Mason RJ, Frank I, Bhindi B, Tollefson MK, Thompson RH, Karnes RJ, Tarrell R, Thapa P, Boorjian SA. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. World J Urol. 2017 Dec; 35 (12):1879-1884 Epub 2017 Sept 14
     View PubMed
216. Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson RH, Boorjian SA. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. J Urol. 2017 Dec; 198 (6):1286-1294 Epub 2017 June 29
     View PubMed
217. Murphy SJ, Kosari F, Karnes RJ, Nasir A, Johnson SH, Gaitatzes AG, Smadbeck JB, Rangel LJ, Vasmatzis G, Cheville JC. Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer. Cancer Res. 2017 Nov 15; 77 (22):6157-6167 Epub 2017 Nov 10
     View PubMed
218. Labbe DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjostrom M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, Ross AE, Bowden M, Huang Y, Gray KP, Feng FY, Spratt DE, Goodrich DW, Eng KH, Ellis L. TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clin Cancer Res. 2017 Nov 15; 23 (22):7072-7083 Epub 2017 Sept 12
     View PubMed
219. Gandaglia G, Briganti A, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M 3rd. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. Eur Urol. 2017 Nov; 72 (5):689-709 Epub 2017 Feb 08
     View PubMed
220. Spahn M, Morlacco A, Boxler S, Joniau S, Briganti A, Montorsi F, Gontero P, Bader P, Frohneberg D, van Poppel H, Karnes RJ, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT). Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. BJU Int. 2017 Nov; 120 (5B):E52-E58 Epub 2017 Mar 26
     View PubMed
221. Bhindi B, Karnes RJ. Author Reply. Urology 2017 Nov; 109:152 Epub 2017 Sept 21
     View PubMed
222. Colicchia M, Karnes RJ. Editorial Comment. J Urol 2017 Nov; 198 (5):1084 Epub 2017 Aug 08
     View PubMed
223. Bhindi B, Carlson RE, Mason RJ, Schulte PJ, Gettman MT, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Leibovich BC, Karnes RJ. Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology. 2017 Nov; 109:145-152 Epub 2017 Aug 18
     View PubMed
224. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol 2017 Nov; 72 (5):660-664 Epub 2017 May 22
     View PubMed
225. Morlacco A, Soligo M, Colicchia M, Nehra A, Karnes RJ. Post-Surgical Strategies for Prostate Cancer: Clinicopathologic and Genomics Criteria European Medical Journal Oncology. 2017.
     
226. Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, Karnes RJ, Chadwick D, van der Kwast T, Boutros PC, Arrowsmith CH, Feng FY, Joshua AM, Zoubeidi A, Cai C, He HH. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Res. 2017 Oct 15; 77 (20):5479-5490 Epub 2017 Sept 15
     View PubMed
227. Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol. 2017 Sep; 72 (3):442-447 Epub 2016 Aug 27
     View PubMed
228. Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, Hamilton RJ, Kulkarni GS, Finelli A, Fleshner NE, Boorjian SA, Karnes RJ. The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017 Sep 1; 177 (9):1273-1286
     View PubMed
229. Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jimenez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget. 2017 Aug 1; 8 (31):50804-50813 Epub 2017 Feb 07
     View PubMed
230. Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, Frank I, Griebling TL, Tollefson MK, Thompson RH, Holzbeierlein JM, Karnes RJ, Boorjian SA. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer. 2017 Aug 1 Epub 2017 Aug 01
     View PubMed
231. Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH, Tollefson MK, Boorjian SA, Pagliaro LC, Karnes RJ. Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy. Clin Genitourin Cancer. 2017 Jul 22 Epub 2017 July 22
     View PubMed
232. Moschini M, Sharma V, Gandaglia G, Dell'Oglio P, Fossati N, Zaffuto E, Montorsi F, Briganti A, Karnes RJ. Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU Int. 2017 Jul; 120 (1):69-75 Epub 2016 Nov 11
     View PubMed
233. Gandaglia G, Karnes RJ, Sivaraman A, Moschini M, Fossati N, Zaffuto E, Dell'Oglio P, Cathelineau X, Montorsi F, Sanchez-Salas R, Briganti A. Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. Urol Oncol. 2017 Jul; 35 (7):461.e7-461.e14 Epub 2017 Mar 27
     View PubMed
234. Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. J Urol. 2017 Jul; 198 (1):86-91 Epub 2017 Jan 24
     View PubMed
235. Gershman B, Meier SK, Jeffery MM, Moreira DM, Tollefson MK, Kim SP, Karnes RJ, Shah ND. Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care. J Urol. 2017 Jul; 198 (1):92-99 Epub 2017 Jan 30
     View PubMed
236. Dalela D, Santiago-Jimenez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. J Clin Oncol. 2017 Jun 20; 35 (18):1982-1990 Epub 2017 Mar 28
     View PubMed
237. Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017 Jun 20; 35 (18):1991-1998 Epub 2017 Mar 30
     View PubMed
238. Tse BWC, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. 2017 Jun 15; 36 (24):3417-3427 Epub 2017 Jan 16
     View PubMed
239. Urbanucci A, Barfeld SJ, Kytola V, Itkonen HM, Coleman IM, Vodak D, Sjoblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 Jun 6; 19 (10):2045-2059
     View PubMed
240. Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Noris Chiorda B, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol. 2017 Jun; 71 (6):886-893 Epub 2016 July 30
     View PubMed
241. Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jimenez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS. Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU Int. 2017 Jun; 119 (6):961-967 Epub 2017 Feb 11
     View PubMed
242. Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clin Genitourin Cancer. 2017 Jun; 15 (3):e299-e309 Epub 2016 Aug 17
     View PubMed
243. Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, Karnes RJ. The Incremental Role of Magnetic Resonance Imaging for Prostate Cancer Staging before Radical Prostatectomy. Eur Urol. 2017 May; 71 (5):701-704 Epub 2016 Aug 28
     View PubMed
244. Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Corrigendum re: "Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications" [Eur Urol 2017;71:55-65]. Eur Urol. 2017 May; 71 (5):e160 Epub 2017 Jan 21
     View PubMed
245. Pan CW, Jin X, Zhao Y, Pan Y, Yang J, Karnes RJ, Zhang J, Wang L, Huang H. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 2017 Apr 13; 36 (8):995-1010 Epub 2017 Mar 09
     View PubMed
246. Muppa P, Gupta S, Frank I, Boorjian SA, Karnes RJ, Thompson RH, Thapa P, Tarrell RF, Herrera Hernandez LP, Jimenez RE, Cheville JC. Prognostic significance of lymphatic, vascular and perineural invasion for bladder cancer patients treated by radical cystectomy. Pathology. 2017 Apr; 49(3):259-266. Epub 2017 Mar 01.
     View PubMed
247. Colicchia M, Morlacco A, Cheville JC, Karnes RJ. Genomic tests to guide prostate cancer management following diagnosis. Expert Rev Mol Diagn. 2017 Apr; 17 (4):367-377 Epub 2017 Mar 13
     View PubMed
248. Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, Cox M, Collins C, Gleave M, Erho N, Alshalafa M, Davicioni E, Nelson C, Gregory-Evans S, Karnes RJ, Jenkins RB, Klein EA, Buttyan R. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget. 2017 Mar 21; 8 (12):18949-18967
     View PubMed
249. Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis ES, Schaeffer EM, Drake CG, Feng F, Ross AE. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017 Mar; 20 (1):28-35 Epub 2016 Nov 01
     View PubMed
250. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71 (3):340-348 Epub 2016 Sept 03
     View PubMed
251. Moschini M, Morlacco A, Kwon E, Rangel LJ, Karnes RJ. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis. 2017 Mar; 20 (1):117-121 Epub 2017 Jan 03
     View PubMed
252. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 1; 97 (3):526-535 Epub 2016 Nov 17
     View PubMed
253. Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson AR, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, Ross AE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubeidi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. Cancer Res. 2017 Feb 15; 77 (4):1021-1034 Epub 2016 Dec 23
     View PubMed
254. Dell'Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, Suardi N, Montorsi F, Briganti A. The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study. Prostate. 2017 Feb; 77 (3):263-273 Epub 2016 Oct 18
     View PubMed
255. White NM, Zhao SG, Zhang J, Rozycki EB, Dang HX, McFadden SD, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N, Arbeit JM, Karnes RJ, Den RB, Davicioni E, Maher CA. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. Eur Urol. 2017 Feb; 71 (2):257-266 Epub 2016 July 22
     View PubMed
256. Klein EA, Santiago-Jimenez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE. Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. J Urol. 2017 Jan; 197 (1):122-128 Epub 2016 Aug 26
     View PubMed
257. Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ. Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with (11)C-Choline Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging. J Urol. 2017 Jan; 197 (1):129-134 Epub 2016 July 20
     View PubMed
258. Gershman B, Van Houten HK, Herrin J, Moreira DM, Kim SP, Shah ND, Karnes RJ. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. Eur Urol. 2017 Jan; 71 (1):55-65 Epub 2016 Mar 16
     View PubMed
259. Sobol I, Zaid HB, Haloi R, Mynderse LA, Froemming AT, Lowe VJ, Davis BJ, Kwon ED, Karnes RJ. Contemporary mapping of post-prostatectomy prostate cancer relapse with c-11-choline positron emission tomography and multiparametric magnetic resonance imaging Journal Of Urology. 2017 Jan; 197(1):129-34. Epub 1900 Jan 01.
     
260. Evangelista L, Zattoni F, Karnes RJ, Novara G, Lowe V. Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis. Nucl Med Commun. 2016 Dec; 37 (12):1223-1231
     View PubMed
261. Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, Kwon E, Karnes RJ. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy. Eur Urol Focus. 2016 Dec; 2 (5):522-531 Epub 2016 Feb 10
     View PubMed
262. Heidenreich A, Moul JW, Shariat S, Karnes RJ. Role of salvage lymph node dissection in prostate cancer. Curr Opin Urol. 2016 Nov; 26 (6):581-9
     View PubMed
263. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016 Nov; 17 (11):1612-1620 Epub 2016 Oct 12
     View PubMed
264. Morlacco A, Karnes RJ. Early salvage radiation therapy post-prostatectomy: key considerations. Future Oncol. 2016 Nov; 12: (22)2579-2587.
     View PubMed
265. Morlacco A, Pan J, Karnes RJ. Risk-prediction tools in prostate cancer: the challenge of tailoring. Asian J Androl 2016 Nov-Dec; 18 (6):952
     View PubMed
266. Westerman ME, Parker WP, Viers BR, Rivera ME, Karnes RJ, Frank I, Tarrell R, Thapa P, Thompson RH, Tollefson MK, Boorjian SA. Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. Urol Oncol. 2016 Nov; 34(11):485.e1-485.e6. Epub 2016 Jul 14.
     View PubMed
267. Kim SP, Karnes RJ, Gross CP, Meropol NJ, Van Houten H, Abouassaly R, Shah ND. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States. Urology. 2016 Nov; 97:111-117 Epub 2016 Aug 12
     View PubMed
268. Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J, Serretta V, Larre S, di Stasi S, Colombo R, Babjuk M, Malmstrom PU, Malats N, Irani J, Baniel J, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Pisano F, Gontero P, Sylvester R. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol. 2016 Nov; 34 (11):484.e19-484.e25 Epub 2016 Sept 14
     View PubMed
269. Zaid HB, Yang DY, Tollefson MK, Frank I, Parker WP, Thompson RH, Karnes RJ, Boorjian SA. Safety and Efficacy of Extended Duration of Thromboembolic Prophylaxis Following Radical Cystectomy: An Initial Institutional Experience. Urol Pract. 2016 Nov; 3 (6):462-467 Epub 2016 Aug 18
     View PubMed
270. McLaren RH, Mynderse LA, Davis BJ, Kwon ED, Lowe VJ, Nathan MA, Karnes R, Parker WP. The Utility of C11 Choline PET/CT in Post-prostatectomy Patients with Biochemical Recurrence: a Comparison to mpMRI. World Jnl of Urol.2016;().
     
271. Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016 Oct; 17 (10):1435-1444 Epub 2016 Aug 27
     View PubMed
272. Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, Briganti A. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in >/=PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96 (2):333-340 Epub 2016 June 18
     View PubMed
273. Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. Eur Urol. 2016 Oct; 70 (4):588-596 Epub 2016 Jan 21
     View PubMed
274. McNair C, Urbanucci A, Comstock CE, Augello MA, Goodwin JF, Launchbury R, Zhao SG, Schiewer MJ, Ertel A, Karnes J, Davicioni E, Wang L, Wang Q, Mills IG, Feng FY, Li W, Carroll JS, Knudsen KE. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 2016 Sep 26;
     View PubMed
275. You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res. 2016 Sep 1; 76 (17):4948-58 Epub 2016 June 14
     View PubMed
276. Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016 Sep; 19 (3):277-82 Epub 2016 May 03
     View PubMed
277. Moreira DM, Gershman B, Rangel LJ, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Gettman MT, Karnes RJ. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. BJU Int. 2016 Sep; 118: (3)379-83.
     View PubMed
278. Westerman ME, Gershman B, Karnes RJ, Thompson RH, Rangel L, Boorjian SA. Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. World J Urol. 2016 Aug; 34 (8):1115-22 Epub 2015 Dec 09
     View PubMed
279. Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016 Jul; 118 (1):44-52 Epub 2015 Nov 06
     View PubMed
280. Zhao J, Zhao Y, Wang L, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 2016 Jun 21; 7 (25):38551-38565
     View PubMed
281. Morlacco A, Karnes RJ. High-risk prostate cancer: the role of surgical management. Crit Rev Oncol Hematol. 2016 Jun; 102:135-43 Epub 2016 Apr 27
     View PubMed
282. Zaid HB, Yang DY, Tollefson MK, Frank I, Winters JL, Thapa P, Parker WP, Thompson RH, Karnes RJ, Boorjian SA. Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion During Open Radical Cystectomy. Urology. 2016 Jun; 92:57-62. Epub 2016 Mar 08.
     View PubMed
283. Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, Tollefson MK, Gettman MT, Carlson RE, Rangel LJ, Karnes RJ. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol. 2016 Jun; 195(6):1754-9. Epub 2015 Dec 23.
     View PubMed
284. Moschini M, Sharma V, Zattoni F, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Kwon ED, Karnes RJ. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. J Urol. 2016 Jun; 195 (6):1773-8 Epub 2015 Dec 23
     View PubMed
285. Moschini M, Karnes RJ, Suardi N, Bianchi M, Pellucchi F, Rocchini L, Damiano R, Serretta V, Salonia A, Montorsi F, Briganti A, Colombo R. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. Clin Genitourin Cancer. 2016 Jun; 14: (3)e245-50.
     View PubMed
286. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K, Murphy DG, Penson DF, Miller DC. Prostate Cancer Registries: Current Status and Future Directions. Eur Urol. 2016 Jun; 69 (6):998-1012 Epub 2015 June 06
     View PubMed
287. Gershman B, Psutka SP, McGovern FJ, Dahl DM, Tabatabaei S, Gettman MT, Frank I, Carlson RE, Rangel LJ, Barry MJ, Blute ML, Karnes RJ. Patient-reported Functional Outcomes Following Open, Laparoscopic, and Robotic Assisted Radical Prostatectomy Performed by High-volume Surgeons at High-volume Hospitals. Eur Urol Focus. 2016 Jun; 2 (2):172-179 Epub 2015 July 15
     View PubMed
288. May EJ, Viers LD, Viers BR, Kawashima A, Kwon ED, Karnes RJ, Froemming AT. Prostate cancer post-treatment follow-up and recurrence evaluation. Abdom Radiol (NY). 2016 May; 41 (5):862-76
     View PubMed
289. Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Capogrosso P, Shariat SF, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. Eur J Surg Oncol. 2016 May; 42 (5):735-43 Epub 2016 Feb 18
     View PubMed
290. Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, Briganti A, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. Urol Oncol. 2016 May; 34: (5)234.e13-9.
     View PubMed
291. Odera M, Joniau S, Guglielmo M, Falcone M, Munegato S, Tosco L, Zattoni F, Karnes R, Gontero P. Outcomes of salvage lymph node dissection for prostate cancer with clinical nodal relapse: Results of a multicentric retrosepective study. EMJ.2016;2:108-115.
     
292. Spans L, Van den Broeck T, Smeets E, Prekovic S, Thienpont B, Lambrechts D, Karnes RJ, Erho N, Alshalalfa M, Davicioni E, Helsen C, Gevaert T, Tosco L, Haustermans K, Lerut E, Joniau S, Claessens F. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget. 2016 Apr 26; 7 (17):24326-38
     View PubMed
293. Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y, Huang H. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep. 2016 Apr 19; 15 (3):599-610 Epub 2016 Apr 07
     View PubMed
294. Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med. 2016 Apr 4; 14:67 Epub 2016 Apr 04
     View PubMed
295. Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer. Clin Cancer Res. 2016 Apr 1; 22 (7):1777-86 Epub 2015 Dec 02
     View PubMed
296. Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, Rubin MA, de Bono J, Knudsen KE, Davicioni E, Feng FY. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. JAMA Oncol. 2016 Apr; 2 (4):471-80
     View PubMed
297. Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. Eur Urol. 2016 Apr; 69 (4):728-733 Epub 2015 Oct 21
     View PubMed
298. Gang X, Yang Y, Zhong J, Jiang K, Pan Y, Karnes RJ, Zhang J, Xu W, Wang G, Huang H. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 2016 Mar 22; 7 (12):15135-49
     View PubMed
299. Leone A, Gershman B, Rotker K, Butler C, Fantasia J, Miller A, Afiadata A, Amin A, Zhou A, Jiang Z, Sebo T, Mega A, Schiff S, Pareek G, Golijanin D, Yates J, Karnes RJ, Renzulli J. Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer Prostatic Dis. 2016 Mar; 19 (1):68-71 Epub 2015 Nov 17
     View PubMed
300. Cockerill PA, Knoedler JJ, Frank I, Tarrell R, Karnes RJ. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int. 2016 Mar; 117 (3):456-62 Epub 2015 May 23
     View PubMed
301. Moschini M, Karnes RJ, Gandaglia G, Luzzago S, Dell'Oglio P, Rossi MS, di Trapani E, La Croce G, Damiano R, Salonia A, Shariat SF, Montorsi F, Briganti A, Gallina A, Colombo R. Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. Urology. 2016 Feb; 88:97-103.
     View PubMed
302. Murphy SJ, Karnes RJ, Kosari F, Castellar BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL, Nasir A, Bergstrahl E, Rangel LJ, Sukov WR, Vasmatzis G, Cheville JC. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer. Mod Pathol. 2016 Feb; 29 (2):143-56 Epub 2015 Nov 27
     View PubMed
303. Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Predicting survival of men with recurrent prostate cancer after radical prostatectomy. Eur J Cancer. 2016 Feb; 54:27-34 Epub 2015 Dec 19
     View PubMed
304. Moschini M, Briganti A, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E, Karnes RJ. Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. Eur Urol. 2016 Feb; 69 (2):193-6 Epub 2015 Aug 08
     View PubMed
305. Hurley PJ, Sundi D, Shinder B, Simons BW, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing C, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An SS, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer EM. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res. 2016 Jan 15; 22 (2):448-58 Epub 2015 Oct 07
     View PubMed
306. Kaushik D, Boorjian SA, Thompson RH, Eisenberg MS, Carlson RE, Bergstralh EJ, Frank I, Gettman MT, Tollefson MK, Karnes RJ. Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. Int Braz J Urol. 2016 Nov-Dec; 42(6):1091-1098.
     View PubMed
307. MacKintosh FR, Sprenkle PC, Walter LC, Rawson L, Karnes RJ, Morrell CH, Kattan MW, Nawaf CB, Neville TB. Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Front Oncol. 2016; 6:157 Epub 2016 June 28
     View PubMed
308. Bernard B, Gershman B, Karnes RJ, Sweeney CJ, Vapiwala N. Approach to Oligometastatic Prostate Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:119-29
     View PubMed
309. Zaid HB, Yang DY, Tollefson MK, Frank I, Parker WP, Thompson RH, Karnes RJ, Boorjian SA. Safety and efficacy of extended duration of thromboembolic prophylaxis following radical cystectomy: an initial institutional experience Urology Practice. 2016; 3(6):462-7. Epub 1900 Jan 01.
     
310. Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Front Surg. 2016; 3:65 Epub 2016 Dec 16
     View PubMed
311. Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, Karnes RJ. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. Eur Urol. 2016 Jan; 69 (1):135-42 Epub 2015 Apr 10
     View PubMed
312. Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer EM, Davicioni E, De Marzo AM, Lotan TL. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res. 2015 Dec 15; 21 (24):5619-29 Epub 2015 Aug 05
     View PubMed
313. Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes R, Gontero P. Is 11C-choline positron emission tomography/computed tomography accurate to detect nodal relapses of prostate cancer after biochemical recurrence? A multicentric study based on pathologic confirmation from salvage lymphadenectomy. j.euf.2015;
     
314. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2015 Dec 1; 6 (38):41045-55
     View PubMed
315. McDonald JS, Carter RE, Karnes RJ, Port JD, Kawashima A, Carlson SK, Bender CE. Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria. AJR Am J Roentgenol. 2015 Nov; 205 (5):1008-15
     View PubMed
316. Spahn M, Boxler S, Joniau S, Moschini M, Tombal B, Karnes RJ. What is the need for prostatic biomarkers in prostate cancer management? Curr Urol Rep. 2015 Oct; 16(10):70.
     View PubMed
317. Alshalalfa M, Crisan A, Vergara IA, Ghadessi M, Buerki C, Erho N, Yousefi K, Sierocinski T, Haddad Z, Black PC, Karnes RJ, Jenkins RB, Davicioni E. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int. 2015 Oct; 116: (4)556-67.
     View PubMed
318. Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes. Eur Urol. 2015 Oct; 68 (4):555-67 Epub 2015 May 08
     View PubMed
319. Viers BR, Lightner DJ, Rivera ME, Tollefson MK, Boorjian SA, Karnes RJ, Thompson RH, O'Neil DA, Hamilton RL, Gardner MR, Bundrick M, Jenkins SM, Pruthi S, Frank I, Gettman MT. Efficiency, satisfaction, and costs for remote video visits following radical prostatectomy: a randomized controlled trial. Eur Urol. 2015 Oct; 68 (4):729-35 Epub 2015 Apr 18
     View PubMed
320. An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, Zhu Y, Wang C, Halling GC, Cheng L, Sukov WR, Karnes RJ, Vasmatzis G, Zhang Q, Zhang J, Cheville JC, Yan J, Sun Y, Huang H. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell. 2015 Sep 17; 59 (6):904-16 Epub 2015 Sept 03
     View PubMed
321. Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, Gomella LG, Graham NA, Vashisht AA, Wohlschlegel JA, Graeber TG, Karnes RJ, Takhar M, Davicioni E, Tomlins SA, Abate-Shen C, Sharifi N, Witte ON, Feng FY, Knudsen KE. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 2015 Jul 13; 28 (1):97-113
     View PubMed
322. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, Briganti A. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015 May; 67 (5):852-63 Epub 2014 Sept 17
     View PubMed
323. Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015 Apr; 33 (4):163.e7-13 Epub 2015 Feb 07
     View PubMed
324. Briganti A, Giannarini G, Karnes RJ, Gandaglia G, Ficarra V, Montorsi F. What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer? Eur Urol. 2015 Apr; 67 (4):597-8 Epub 2014 Oct 01
     View PubMed
325. Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015 Mar 10; 33 (8):944-51 Epub 2015 Feb 09
     View PubMed
326. Jatkoe TA, Karnes RJ, Freedland SJ, Wang Y, Le A, Baden J. A urine-based methylation signature for risk stratification within low-risk prostate cancer. Br J Cancer. 2015 Mar 3; 112 (5):802-8 Epub 2015 Feb 19
     View PubMed
327. Kim SP, Gross CP, Smaldone MC, Han LC, Van Houten H, Lotan Y, Svatek RS, Thompson RH, Karnes RJ, Trinh QD, Kutikov A, Shah ND. Perioperative outcomes and hospital reimbursement by type of radical prostatectomy: results from a privately insured patient population. Prostate Cancer Prostatic Dis. 2015 Mar; 18 (1):13-7 Epub 2014 Oct 14
     View PubMed
328. Clifton MM, Psutka SP, Boorjian SA, Cheville JC, Thapa P, Thompson RH, Tollefson MK, Karnes RJ, Frank I. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2015 Mar; 33 (3):373-9 Epub 2014 May 15
     View PubMed
329. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol. 2015 Feb; 67 (2):326-33 Epub 2014 July 02
     View PubMed
330. Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2015 Feb; 67 (2):319-25 Epub 2014 Mar 21
     View PubMed
331. Evangelista L, Zattoni F, Rossi E, Karnes RJ, Lowe V. Early detection of prostate cancer relapse by biochemistry and diagnostic imaging. Q J Nucl Med Mol Imaging. 2015; 59(4):359-73.
     View PubMed
332. Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One. 2015; 10 (3):e0116866 Epub 2015 Apr 02
     View PubMed
333. Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol. 2015 Jan; 67 (1):157-164 Epub 2014 Jan 25
     View PubMed
334. Karnes RJ, Murphy CR, Bergstralh EJ, DiMonte G, Cheville JC, Lowe VJ, Mynderse LA, Kwon ED. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol. 2015 Jan; 193 (1):111-6 Epub 2014 Aug 20
     View PubMed
335. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmstrom PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015 Jan; 67 (1):74-82 Epub 2014 July 16
     View PubMed
336. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, Briganti A. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014 Dec 10; 32 (35):3939-47 Epub 2014 Sept 22
     View PubMed
337. Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, Klein EA, Jenkins RB, Chinnaiyan AM, Feng FY. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 2014 Dec; 15 (13):1469-1480 Epub 2014 Nov 17
     View PubMed
338. Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L, Karnes RJ. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):332-7. Epub 2014 Aug 26.
     View PubMed
339. Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol. 2014 Dec; 66: (6)1116-24.
     View PubMed
340. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014 Dec; 66 (6):1157-64 Epub 2014 Feb 26
     View PubMed
341. Sprung J, Scavonetto F, Yeoh TY, Kramer JM, Karnes RJ, Eisenach JH, Schroeder DR, Weingarten TN. Outcomes after radical prostatectomy for cancer: a comparison between general anesthesia and epidural anesthesia with fentanyl analgesia: a matched cohort study. Anesth Analg. 2014 Oct; 119 (4):859-866
     View PubMed
342. Yeoh TY, Scavonetto F, Weingarten TN, Karnes RJ, van Buskirk CM, Hanson AC, Schroeder DR, Sprung J. Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy. Transfusion. 2014 Sep; 54 (9):2175-81 Epub 2014 Mar 24
     View PubMed
343. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014 Sep; 66 (3):479-86 Epub 2013 Dec 12
     View PubMed
344. Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014 Aug; 66 (2):265-72 Epub 2014 Feb 26
     View PubMed
345. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol. 2014 Aug; 66 (2):191-9 Epub 2013 May 22
     View PubMed
346. Kim SP, Gross CP, Nguyen PL, Smaldone MC, Shah ND, Karnes RJ, Thompson RH, Han LC, Yu JB, Trinh QD, Ziegenfuss JY, Sun M, Tilburt JC. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care. 2014 Jul; 52(7):579-85.
     View PubMed
347. Scavonetto F, Yeoh TY, Umbreit EC, Weingarten TN, Gettman MT, Frank I, Boorjian SA, Karnes RJ, Schroeder DR, Rangel LJ, Hanson AC, Hofer RE, Sessler DI, Sprung J. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth. 2014 Jul; 113 Suppl 1:i95-102 Epub 2013 Dec 16
     View PubMed
348. Kim SP, Gross CP, Nguyen PL, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):163-9. Epub 2014 Feb 25.
     View PubMed
349. Breau RH, Karnes RJ, Farmer SA, Thapa P, Cagiannos I, Morash C, Frank I. Progression to detrusor muscle invasion during urothelial carcinoma surveillance is associated with poor prognosis. BJU Int. 2014 Jun; 113(6):900-6. Epub 2013 Nov 27.
     View PubMed
350. Han LC, Delpe S, Shah ND, Ziegenfuss JY, Tilburt JC, Karnes RJ, Nguyen PL, Gross CP, Yu JB, Trinh QD, Sun M, Ranasinghe WK, Kim SP. Perceptions of radiation oncologists and urologists on sources and type of evidence to inform prostate cancer treatment decisions. Int J Radiat Oncol Biol Phys. 2014 Jun 1; 89(2):277-83. Epub 2014 Mar 27.
     View PubMed
351. Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM. Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol. 2014 Jun; 191 (6):1721-7 Epub 2013 Dec 14
     View PubMed
352. Reynolds JP, Voss JS, Kipp BR, Karnes RJ, Nassar A, Clayton AC, Henry MR, Sebo TJ, Zhang J, Halling KC. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol. 2014 Jun; 122(6):459-67. Epub 2014 Mar 06.
     View PubMed
353. Knoedler JJ, Karnes RJ, Thompson RH, Rangel LJ, Bergstralh EJ, Boorjian SA. The association of tumor volume with mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17 (2):144-8 Epub 2014 Jan 28
     View PubMed
354. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014 May; 27 (5):758-64 Epub 2013 Nov 01
     View PubMed
355. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU Int. 2014 May; 113: (5b)E106-11.
     View PubMed
356. Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV. Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther. 2014 May; 13 (5):1067-77 Epub 2014 Mar 27
     View PubMed
357. Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res. 2014 Mar 15; 74 (6):1870-1880 Epub 2014 Jan 30
     View PubMed
358. Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 2014 Mar; 17 (1):64-9 Epub 2013 Oct 22
     View PubMed
359. Tollefson MK, Karnes RJ, Rangel L, Carlson R, Boorjian SA. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol. 2014 Mar; 191(3):646-51. Epub 2013 Oct 17.
     View PubMed
360. Murphy CR, Karnes RJ. Bladder cancer in males: a comprehensive review of urothelial carcinoma of the bladder. Journal Of Mens Health. 2014 Mar; 11(1):18-27.
     
361. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, Briganti A. Predicting survival of patients with node-positive prostate cancer following multimodal treatment. Eur Urol. 2014 Mar; 65 (3):554-62 Epub 2013 Sept 27
     View PubMed
362. Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc. 2014 Mar; 89 (3):308-18 Epub 2014 Jan 31
     View PubMed
363. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol. 2014 Jan; 32(1):43.e1-7. Epub 2013 Jun 28.
     View PubMed
364. Hubanks JM, Boorjian SA, Frank I, Gettman MT, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. UROL. ONCOL. 2014; 32(1):26.e1-7.
     
365. Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013 Dec; 190 (6):2047-53 Epub 2013 June 11
     View PubMed
366. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Karnes RJ, St Sauver J. Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. Urology. 2013 Dec; 82(6):1211-7. Epub 2013 Oct 19.
     View PubMed
367. Parker AS, Thiel DD, Bergstralh E, Carlson RE, Rangel LJ, Joseph RW, Diehl N, Karnes RJ. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013 Dec; 16(4):352-6. Epub 2013 Aug 20.
     View PubMed
368. Eisenberg MS, Karnes RJ, Kaushik D, Rangel L, Bergstralh EJ, Boorjian SA. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy. J Urol. 2013 Nov; 190(5):1735-41. Epub 2013 May 29.
     View PubMed
369. Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol. 2013 Nov; 31 (8):1483-8 Epub 2012 May 10
     View PubMed
370. Woodrum DA, Kawashima A, Karnes RJ, Davis BJ, Frank I, Engen DE, Gorny KR, Felmlee JP, Callstrom MR, Mynderse LA. Magnetic resonance imaging-guided cryoablation of recurrent prostate cancer after radical prostatectomy: initial single institution experience. Urology. 2013 Oct; 82 (4):870-5 Epub 2013 Aug 01
     View PubMed
371. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol. 2013 Oct; 64: (4)557-64.
     View PubMed
372. Kim SP, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND, Frank I, Smaldone MC, Gross CP, Yu JB, Trinh QD, Sun M, O'Malley RL, Nguyen PL. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology. 2013 Oct; 82: (4)807-12.
     View PubMed
373. Linder BJ, Frank I, Umbreit EC, Shimko MS, Fernandez N, Rangel LJ, Karnes RJ. Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. Int J Urol 2013 Sep; 20 (9):860-4 Epub 2012 Dec 20
     View PubMed
374. Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int. 2013 Aug; 112 (4):478-84 Epub 2013 Mar 01
     View PubMed
375. Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer. Int J Urol. 2013 Aug; 20(8):798-805. Epub 2012 Dec 20.
     View PubMed
376. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol. 2013 Jul; 64(1):11-6. Epub 2012 Aug 20.
     View PubMed
377. Joniau S, Tosco L, Briganti A, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M, Van Poppel H, European Multicenter Prostate Cancer Clinical and Translational research group. Results of surgery for high-risk prostate cancer. Curr Opin Urol. 2013 Jul; 23: (4)342-8.
     View PubMed
378. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, Sukov WR, Karnes RJ, Vasmatzis G. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013 Jun 1; 73 (11):3275-84 Epub 2013 May 21
     View PubMed
379. Weight CJ, Kim SP, Jacobson DJ, McGree ME, Boorjian SA, Thompson RH, Leibovich BC, Karnes RJ, St Sauver J. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol. 2013 Jun; 63(6):1021-7. Epub 2013 Jan 04.
     View PubMed
380. Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, Trinh QD, Sun M, Boorjian SA, Beebe TJ, Tilburt JC. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists. J Urol. 2013 Jun; 189(6):2092-8. Epub 2012 Dec 03.
     View PubMed
381. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013 May; 189 (5):1707-12 Epub 2012 Nov 15
     View PubMed
382. Mitchell CR, Lowe VJ, Rangel LJ, Hung JC, Kwon ED, Karnes RJ. Operational characteristics of (11)c-choline positron emission tomography/computerized tomography for prostate cancer with biochemical recurrence after initial treatment. J Urol. 2013 Apr; 189 (4):1308-13 Epub 2012 Oct 30
     View PubMed
383. Joniau S, Van der Eeckt K, Briganti A, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H, European Multicenter Prostate Cancer Clinical and Translational research Group (EMPaCT). Current role of surgery for high risk prostate cancer. Arch Esp Urol. 2013 Apr; 66(3):259-73, 259-74.
     View PubMed
384. Kim SP, Boorjian SA, Shah ND, Weight CJ, Tilburt JC, Han LC, Thompson RH, Trinh QD, Sun M, Moriarty JP, Karnes RJ. Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy. J Urol. 2013 Feb; 189 (2):514-20 Epub 2012 Dec 17
     View PubMed
385. Bruner B, Nehra A, Rangel L, Bailey C, Bergstralh E, Blute M, Karnes RJ. Association of preoperative testosterone levels with biochemical failure in men undergoing radical prostatectomy. Journal of Men's Health. 2013; 10(4):129-33.
     
386. Gomez CR, Kosari F, Munz JM, Schreiber CA, Knutson GJ, Ida CM, El Khattouti A, Karnes RJ, Cheville JC, Vasmatzis G, Vuk-Pavlovic S. Prognostic value of discs large homolog 7 transcript levels in prostate cancer. PLoS One. 2013; 8 (12):e82833 Epub 2013 Dec 09
     View PubMed
387. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8: (6)e66855.
     View PubMed
388. Siddique HR, Parray A, Tarapore RS, Wang L, Mukhtar H, Karnes RJ, Deng Y, Konety BR, Saleem M. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS One. 2013; 8: (5)e60664.
     View PubMed
389. Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Rhim JS, Konety BR, Saleem M. BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer. PLoS One. 2013; 8: (1)e52993.
     View PubMed
390. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int. 2012 Dec; 110(11):1709-13. Epub 2012 Aug 30.
     View PubMed
391. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012 Nov; 188(5):1761-6. Epub 2012 Sep 19.
     View PubMed
392. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP, Tollefson MK, Shippee ND, Frank I. Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int. 2012 Oct; 110 (8):1163-8 Epub 2012 Mar 22
     View PubMed
393. Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, Feldman AL, Eckloff BW, Karnes RJ, Vasmatzis G. Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012 Oct; 19 (5):395-406 Epub 2012 Sept 18
     View PubMed
394. Karnes RJ, Fernandez CA, Shuber AP. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Mayo Clin Proc. 2012 Sep; 87 (9):835-42 Epub 2012 Aug 09
     View PubMed
395. Weight CJ, Kim SP, Karnes RJ, Bergstralh EJ, Cheville JC, Leibovich BC. A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis. Urology. 2012 Aug; 80(2):484.e17-22. Epub 2012 Apr 13.
     View PubMed
396. Kosari F, Cheville JC, Ida CM, Karnes RJ, Leontovich AA, Sebo TJ, Erdogan S, Rodriguez E, Murphy SJ, Vasmatzis G. Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer. Am J Pathol. 2012 Jul; 181 (1):34-42 Epub 2012 May 26
     View PubMed
397. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012 Jun; 187 (6):2011-7 Epub 2012 Apr 11
     View PubMed
398. Nabhan M, Kim SP, Shah ND, Bagniewski SM, Shi Q, Karnes RJ, Weight CJ, Davis BJ, Kohli M, Tilburt JC. The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc. 2012 Jun; 87 (6):540-7
     View PubMed
399. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol. 2012 May; 61: (5)961-71.
     View PubMed
400. Hubanks JM, Umbreit EC, Karnes RJ, Myers RP. Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series. Eur Urol. 2012 May; 61 (5):878-84 Epub 2011 Dec 05
     View PubMed
401. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol. 2012 Apr; 61 (4):664-75 Epub 2011 Dec 07
     View PubMed
402. Karnes R, Choo C, Call JA. Current Management Approach for Patients with PSA Relapse Following Radical Prostatectomy Interventional Oncology Society Journal.2012;2(1)37-47.
     
403. Briganti A, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol. 2012 Mar; 61: (3)584-92.
     View PubMed
404. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):56-62. Epub 2011 Aug 02.
     View PubMed
405. Dimonte G, Bergstralh EJ, Bolander ME, Karnes RJ, Tindall DJ. Use of tumor dynamics to clarify the observed variability among biochemical recurrence nomograms for prostate cancer. Prostate. 2012 Feb; 72: (3)280-90.
     View PubMed
406. Hertzig LL, Choo RC, Lightner DJ, Karnes RJ. Multimodal Treatment Approach to Advanced Female Urethral Squamous Cell Carcinoma Open Journal of Urology. 2012 29 Aug; 2(3):139-43.
     
407. Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, Briganti A, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schroder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. Adv Urol. 2012; 2012:612707. Epub 2012 Jan 31.
     View PubMed
408. Fernandez CA, Millholland JM, Zwarthoff EC, Feldman AS, Karnes RJ, Shuber AP. A noninvasive multi-analyte diagnostic assay: Combining protein and DNA markers to stratify bladder cancer patients. Open Access Journal of Urology. 2012; 4(1):17-26.
     
409. Kim SP, Karnes RJ. An Editorial Response to the USPTF. Prostate cancer screening: The case for patient-centered shared decision-making. Journal of Men's Health. 2012; 9(1):5-8.
     
410. Gleeson FC, Clain JE, Karnes RJ, Rajan E, Topazian MD, Wang KK, Levy MJ. Endoscopic-ultrasound-guided tissue sampling facilitates the detection of local recurrence and extra pelvic metastasis in pelvic urologic malignancy. Diagn Ther Endosc. 2012; 2012:219521 Epub 2012 June 19
     View PubMed
411. Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV. Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells. Evid Based Complement Alternat Med. 2012; 2012:303019 Epub 2012 Feb 22
     View PubMed
412. Inman BA, Frank I, Boorjian SA, Akornor JW, Karnes RJ, Leibovich BC, Blute ML, Bergstralh EJ. Dynamic prediction of metastases after radical prostatectomy for prostate cancer. BJU Int. 2011 Dec; 108: (11)1762-8.
     View PubMed
413. Mitchell CR, Umbreit EC, Rangel LJ, Bergstralh EJ, Karnes RJ. Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy? Urology. 2011 Oct; 78 (4):868-72 Epub 2011 Aug 16
     View PubMed
414. Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV. Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer. AAPS J. 2011 Sep; 13 (3):365-77 Epub 2011 May 11
     View PubMed
415. Siddique HR, Mishra SK, Karnes RJ, Saleem M. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy. Clin Cancer Res. 2011 Aug 15; 17(16):5379-91. Epub 2011 Jun 28.
     View PubMed
416. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol. 2011 Aug; 60: (2)205-10.
     View PubMed
417. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011 Jul 1; 117 (13):2883-91 Epub 2011 Jan 10
     View PubMed
418. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59 (6):893-9 Epub 2011 Feb 22
     View PubMed
419. Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol. 2011 May; 59: (5)832-40.
     View PubMed
420. Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ. Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5. Epub 2010 Dec 03.
     View PubMed
421. Tollefson MK, Gettman MT, Karnes RJ, Frank I. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol. 2011 May; 185 (5):1686-90 Epub 2011 Mar 21
     View PubMed
422. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, Munz JM, Kosari F, Vasmatzis G. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res. 2010 Nov 15; 70 (22):8994-9002 Epub 2010 Nov 09
     View PubMed
423. Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9.
     View PubMed
424. Karnes RJ, Breau RH, Lightner DJ. Surgery for urethral cancer. Urol Clin North Am. 2010 Aug; 37(3):445-57.
     View PubMed
425. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A, Lieber MM, St Sauver JL. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol. 2010 Aug; 184(2):494-9. Epub 2010 Jun 17.
     View PubMed
426. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105 (10):1381-5 Epub 2009 Oct 26
     View PubMed
427. Donkena KV, Karnes RJ, Young CY. Vitamins and prostate cancer risk. Molecules. 2010 Mar 12; 15 (3):1762-83
     View PubMed
428. Boorjian SA, Karnes RJ, Crispen PL, Carlson RE, Rangel LJ, Bergstralh EJ, Blute ML. The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol. 2010 Mar; 183(3):1003-9. Epub 2010 Jan 21.
     View PubMed
429. Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML. Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210 (2):232-9 Epub 2009 Dec 03
     View PubMed
430. Karnes RJ, Hatano T, Blute ML, Myers RP. Radical prostatectomy for high-risk prostate cancer. Jpn J Clin Oncol. 2010 Jan; 40(1):3-9. Epub 2009 Oct 19.
     View PubMed
431. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009 Dec; 182: (6)2708-14.
     View PubMed
432. He M, Vanaja DK, Karnes RJ, Young CY. Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. Prostate. 2009 Nov 1; 69 (15):1643-50
     View PubMed
433. McGee SM, Boorjian SA, Karnes RJ. Carcinosarcoma of the prostate replacing the entire lower genitourinary tract. Urology. 2009 Sep; 74(3):540-1. Epub 2009 Jul 08.
     View PubMed
434. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol. 2009 Jul; 182: (1)125-32.
     View PubMed
435. Gong A, He M, Krishna Vanaja D, Yin P, Karnes RJ, Young CY. Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells. Mol Nutr Food Res. 2009 Jul; 53 (7):878-86
     View PubMed
436. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest. 2009 Jun; 27 (5):549-60
     View PubMed
437. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, Blute ML, Sebo TJ, Tindall DJ, Kwon ED, Karnes RJ. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009 Mar 15; 15 (6):2174-80 Epub 2009 Mar 10
     View PubMed
438. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn. 2009 Mar; 11 (2):148-54 Epub 2009 Jan 29
     View PubMed
439. Gettman MT, Pereira CW, Lipsky K, Wilson T, Arnold JJ, Leibovich BC, Karnes RJ, Dong Y. Use of high fidelity operating room simulation to assess and teach communication, teamwork and laparoscopic skills: initial experience. J Urol. 2009 Mar; 181 (3):1289-96 Epub 2009 Jan 18
     View PubMed
440. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML. The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol. 2009 Jan; 181(1):95-104; discussion 104. Epub 2008 Nov 13.
     View PubMed
441. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. Cancer. 2008 Oct 1; 113 (7):1544-51
     View PubMed
442. Kipp BR, Tyner HL, Campion MB, Voss JS, Karnes RJ, Sebo TJ, Halling KC, Zhang J. Chromosomal alterations detected by fluorescence in situ hybridization in urothelial carcinoma and rarer histologic variants of bladder cancer. Am J Clin Pathol. 2008 Oct; 130 (4):552-9
     View PubMed
443. Miller J, Karnes RJ. Primary clear-cell adenocarcinoma of the proximal female urethra: case report and review of the literature. Clin Genitourin Cancer. 2008 Sep; 6: (2)131-3.
     View PubMed
444. Voss JS, Kipp BR, Krueger AK, Clayton AC, Halling KC, Karnes RJ, Henry MR, Sebo TJ. Changes in specimen preparation method may impact urine cytologic evaluation. Am J Clin Pathol. 2008 Sep; 130(3):428-33.
     View PubMed
445. Cheville JC, Karnes RJ, Therneau TM, Kosari F, Munz JM, Tillmans L, Basal E, Rangel LJ, Bergstralh E, Kovtun IV, Savci-Heijink CD, Klee EW, Vasmatzis G. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol. 2008 Aug 20; 26 (24):3930-6
     View PubMed
446. Gettman MT, Karnes RJ, Arnold JJ, Klipfel JM, Vierstraete HT, Johnson ME, Johnson DR, Leibovich BC. Urology resident training with an unexpected patient death scenario: experiential learning with high fidelity simulation. J Urol. 2008 Jul; 180(1):283-8; discussion 288. Epub 2008 May 21.
     View PubMed
447. Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ, Frank I, Gettman MT. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol. 2008 Jul; 22(7):1471-6.
     View PubMed
448. Karnes RJ, Blute ML. Surgery insight: management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol. 2008 Jun; 5 (6):329-39 Epub 2008 May 13
     View PubMed
449. Thompson RH, Leibovich BC, Karnes RJ, Bergstralh EJ, Blute ML. Radical retropubic prostatectomy in immunosuppressed transplant recipients. J Urol. 2008 Apr; 179 (4):1349-52; discussion 1352-3 Epub 2008 Mar 04
     View PubMed
450. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr; 179 (4):1354-60; discussion 1360-1 Epub 2008 Mar 04
     View PubMed
451. Kipp BR, Halling KC, Campion MB, Wendel AJ, Karnes RJ, Zhang J, Sebo TJ. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol. 2008 Apr; 179 (4):1296-301; discussion 1301 Epub 2008 Mar 04
     View PubMed
452. Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM, Tillmans L, Slezak J, Karnes RJ, Cheville JC, Vasmatzis G. Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res. 2008 Mar 15; 14 (6):1734-43
     View PubMed
453. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int. 2008 Feb; 101(3):299-304. Epub 2007 Oct 08.
     View PubMed
454. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. Epub 2007 Jul 16.
     View PubMed
455. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007 Aug 15; 67 (16):7893-900 Epub 2007 Aug 08
     View PubMed
456. Blute ML, Boorjian SA, Leibovich BC, Lohse CM, Frank I, Karnes RJ. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. J Urol. 2007 Aug; 178 (2):440-5; discussion 444 Epub 2007 June 11
     View PubMed
457. Miller J, Nwokeji C, Cunningham D, Karnes RJ:. Transitional Cell Carcinoma of the Renal Pelvis with Vena Caval Tumor Thrombus. Issues in Urology. October 2006; 18(5).
     
458. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr Pharm Des. 2006; 12: (7)807-17.
     View PubMed
459. Gillett MD, Cheville JC, Karnes RJ, Lohse CM, Kwon ED, Leibovich BC, Zincke H, Blute ML. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005 Jun; 173 (6):1893-6
     View PubMed
460. Kramer SA, Rathbun SR, Elkins D, Karnes RJ, Husmann DA. Double-blind placebo controlled study of alpha-adrenergic receptor antagonists (doxazosin) for treatment of voiding dysfunction in the pediatric population. J Urol. 2005 Jun; 173 (6):2121-4; discussion 2124
     View PubMed
461. Kipp BR, Karnes RJ, Brankley SM, Harwood AR, Pankratz VS, Sebo TJ, Blute MM, Lieber MM, Zincke H, Halling KC. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol. 2005 Feb; 173: (2)401-4.
     View PubMed
462. Frank I, Cheville JC, Blute ML, Lohse CM, Karnes RJ, Weaver AL, Sebo TJ, Nehra A, Zincke H. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Cancer. 2004 Oct 15; 101 (8):1803-8
     View PubMed
463. Frank I, Cheville JC, Blute ML, Lohse CM, Nehra A, Weaver AL, Karnes RJ, Zincke H. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer. 2003 May 15; 97 (10):2425-31
     View PubMed
464. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002 May; 167 (5):2001-6
     View PubMed
465. Karnes RJ, Nehra A. Ventral, subcoronal, and penoscrotal penile approach for semirigid rod penile prostheses Atlas of the Urologic Clinics of North America. 2002; 10: (2)181-8.
     
466. Karnes RJ, Gettman MT, Anderson PM, Lager DJ, Blute ML. Primitive neuroectodermal tumor (extraskeletal Ewing's sarcoma) of the kidney with vena caval tumor thrombus. J Urol. 2000 Sep; 164 (3 Pt 1):772
     View PubMed